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Preface
An agreement has been signed by the Dutch Expert Committee on Occupational
Standards (DECOS) of the Health Council of the Netherlands and the Nordic
Expert Group for Criteria Documentation of Health Risks from Chemicals (NEG).
The purpose of the agreement is to write joint scientific criteria documents, which
could be used by the national regulatory authorities in both the Netherlands and in
the Nordic countries.
The document on health effects of formaldehyde was written by Anton Wibowo,
Coronel Institute, Academic Medical Centre, University of Amsterdam, the
Netherlands, and has been reviewed by DECOS as well as by NEG.
The joint document is published separately by DECOS and NEG. The NEG
version presented herein has been adapted to the requirements of NEG and the
format of Arbete och Hälsa. The editorial work and technical editing has been
carried out by Anna-Karin Alexandrie, and Jill Järnberg, scientific secretary of
NEG, at the National Institute for Working Life in Sweden.
We acknowledge the Nordic Council of Ministers for its financial support of
this project.
G.J. Mulder G. Johanson
Chairman Chairman
DECOS NEG
Abbreviations
ACGIH American Conference of Governmental Industrial Hygienists
CI confidence interval
CNS central nervous system
CRR combined relative risk
EPA United States Environmental Protection Agency
FEV1 forced expiratory volume in one second
FEV3 forced expiratory volume in three seconds
FVC forced vital capacity
IARC International Agency for Research on Cancer
IHF Industrial Health Foundation
IPCS International Programme on Chemical Safety
LOAEL lowest observed adverse effect level
MAK maximale Arbeitsplatzkonzentration
NIOSH National Institute for Occupational Safety and Health
NOAEL no observed adverse effect level
OR odds ratio
OSHA Occupational Safety and Health Association
RD50 concentration associated with a 50% decrease in respiratory rate
SMR standard mortality ratio
SPIR standardised proportionate incidence ratio
SRR standardised rate ratio
TLV threshold limit value
TWA time weighted average
WHO World Health Organisation
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11. Introduction
Formaldehyde is a colourless gas at room temperature and normal atmospheric
pressure. It is flammable, reactive and polymerises readily at room temperature. It
forms explosive mixtures with air and oxygen at atmospheric pressure. The
substance occurs naturally in the environment and is produced physiologically by
mammalian cells during metabolism.
Formaldehyde is used as a raw material in chemical reactions, and as an
intermediate in the manufacture of numerous products. It has also a medical
application as a disinfectant and is used as a preservative in various consumer
products.
A criteria document on formaldehyde was written for the Nordic Expert Group
for Documentation of Occupational Exposure Limits (NEG) in 1982 (66).
The present document is a co-production between NEG and the Dutch Expert
committee on Occupational Standards (DECOS) hereafter called the committees,
and the document is an up-date of the previus DECOS publication from 1987
(34).
2. Identity, properties and monitoring
2.1 Identity and chemical properties
Chemical formula: CH2O (HCHO)
CAS registry number: 50-00-0
RTECS registry number: LP 8925000
UN number: 1198, 2209, 2213
EC numbers: 605-001-01 (sol 5% to < 25%)
605-001-02 (sol 1% to < 5%)
605-001-005 (sol ≥ 25%)
IUPAC name: methanal
Common synonyms: formaldehyde, methylene oxide,
oxymethylene, methylaldehyde, oxomethane
Common names for
solutions of formaldehyde: formalin, formol
2.2 Physical characteristics (27, 59)
Relative molecular mass: 30.03
Boiling point: -20°C
Melting point: -92°C
Relative density (water=1): 0.8
Solubility in water: miscible
Relative vapour density (air = 1): 1.08
Flash point: flammable gas, 60°C
2Auto-ignition temperature: 300°C
Explosive limits: 7-73 vol% in air
Vapour pressure: 0.2 kPa at 20°C, 101.3 kPa at -19°C,
52.6 kPa at -33°C
Conversion factors: 1 ppm  = 1.2 mg/m3
(25°C, 1066 mbar) 1 mg/m3 = 0.83 ppm
Formaldehyde is a colourless gas at room temperature and normal atmospheric
pressure. It is flammable, reactive and readily polymerises at room temperature. It
forms explosive mixtures with air and oxygen at atmospheric pressure.
Formaldehyde is present in aqueous solutions as a hydrate and tends to
polymerise. At room temperature, and a formaldehyde content of 30% and more,
the polymers precipitate and render the solution turbid. Under atmospheric
conditions, formaldehyde is readily photo-oxidised in sunlight to carbon dioxide.
2.3 Validated analytical methods
2.3.1 Environmental exposure monitoring
The most widely used methods for the determination of formaldehyde are based
on photometric measurements. The sampling method depends on the medium in
which formaldehyde is to be determined.
The International Programme on Chemical Safety/World Health Organisation
(IPCS/WHO) reported a number of different methods for determination of
formaldehyde, using spectrophotometric, colorimetric, fluorometric, high
performance liquid chromatographic, polarographic, gas chromatographic,
infrared, and visual analytical methods (59). On each method the analytical
sensitivity was reported.
Formaldehyde in air may be collected in an absorbing medium by diffusion
(passive sampling). Aqueous or 50% 1-propanol solutions are also used for
formaldehyde sampling. For active sampling, aqueous solutions and solutions
containing sulphite, 3-methyl-2-benzothiazolene hydrazine, chromotropic acid or
2,4-dinitrophenylhydrazine are generally used as the absorbing solution. For
passive sampling sodium bisulphite, triethanolamine and 2,4-dinitrophenyl-
hydrazine are used and sorbents such as silica gel, aluminium oxide and activated
carbon, sometimes specially treated, may be useful for taking samples at the
workplace.
2.3.2 Biological exposure monitoring
Until present, biological monitoring methods for exposure to formaldehyde have
not been fully examined. Considering the critical effects and the target organs
biological monitoring seems to be irrelevant.
33. Sources
3.1 Natural sources
Formaldehyde is naturally formed in the troposphere during the oxidation of
hydrocarbons.
Formaldehyde is one of the volatile compounds formed in the early stages of
decomposition of plant residues in the soil.
3.2 Man-made sources
The most important man-made source of formaldehyde is automotive exhaust
from engines not fitted with catalytic converters.
3.2.1 Production
Formaldehyde is produced by oxidising methanol using two different procedures:
(a) oxidation with silver crystals or silver nets at 600-720°C, and (b) oxidation
with iron molybdenum oxides at 270-380°C. Formaldehyde can be produced as a
by-product of hydrocarbon oxidation processes.
In 1992 worldwide formaldehyde production was estimated to be 12 million
tonnes. Major formaldehyde producing countries in 1990 were the United States
and Japan with 3 million and 1.5 million tonnes, respectively. Other production
numbers were: Germany 680 000; China 467 000; Sweden 244 000; Finland
48 000 and Denmark 3 000 tonnes (58).
3.2.2 Uses
Formaldehyde is an inexpensive starting material for a number of chemical
reactions, and a large number of products are made using formaldehyde as a base.
As an intermediate product, formaldehyde is used in the manufacture of
particleboard, fibreboard, plywood, paper treatment, textile treatment, moulding
compounds, surface coatings, foam, plywood adhesive, insulation, foundry
binders, phenolic thermosetting, resin curing agents, explosives, lubricants,
automobile applications, plumbing components, alkyd resins, synthetic lubricants,
tall oil esters, foundry resins and controlled release fertilisers.
Furthermore, formaldehyde has medical applications as a preservative and
disinfectant and it is used as a preservative in various consumer products.
4. Exposure
4.1 General population
The possible sources of exposure to formaldehyde of the general population are
tobacco smoke, automobile emissions, building and insulating materials, food
products, cosmetics, household cleaning agents, medicinal products, and in
nature (59). Routes of exposure are inhalation, ingestion and dermal absorption.
4The IPCS/WHO made the following estimation on the contribution of various
atmospheric environments to the total formaldehyde intake by inhalation of an
individual (Table 1) (59).
Guicherit and Schulting reported an average concentration of 7.4 µg/m3 (0.006
ppm) of formaldehyde in the ambient air of Terschelling Island, Delft and
Rotterdam, the Netherlands, in the 1980s (45).
The IPCS/WHO estimated that smoking 20 cigarettes per day would lead to an
average daily intake of 1 mg formaldehyde per day (59). Formaldehyde produced
by cigarettes may also mean considerable exposure for non-smokers through
passive smoking. The more so since it has been reported that the effects of
gaseous formaldehyde are potentiated by smoke particles and aerosols.
4.2 Working population
Exposure to formaldehyde in the workplace can be caused by either the produc-
tion or handling of this compound or products containing it. Concentrations of
formaldehyde in occupational settings in the United States were reported by the
ICPS/WHO (59), these are presented in Appendix 1.
The following represents more recent occupational exposure data.
Akbar-Khanzadeh et al. reported concentrations ranging from 0.08 to 3.53
mg/m3 (0.07-2.94 ppm) formaldehyde in a gross anatomy laboratory of the
Medical College in Ohio, United States (3). The 8-hour time weighted average
(TWA) exposure of 31.7% of the subjects working in the laboratory exceeded the
action level of 0.6 mg/m3 (0.5 ppm) set by the Occupational Safety and Health
Association (OSHA).
The mean concentration of formaldehyde in area samples of an anatomy
laboratory in Singapore was 0.6 mg/m3 (0.5 ppm) with a range of 0.5-0.7 mg/m3
Table 1. Contribution of various atmospheric environments to the total formaldehyde
intake by inhalation of an individual (59).
Source Average intake (mg/day)
Ambient air (10% of the time)  0.02
Indoor air, home (65% of the time)
prefabricated (particle board) 1-10
conventional home 0.5-2
Workplace air (25% of the time)
without occupational exposurea 0.2-0.8
occupational exposure to 1 mg/m3 5
environmental tobacco smoke 0.1-1.0
Smoking (20 cigarettes/day) 1.0
a
 Assuming the normal formaldehyde concentration in conventional buildings.
5(0.4-0.6 ppm). The mean of personal samples was 0.9 mg/m3 (0.74 ppm) with a
range of 0.5-1.4 mg/m3 (0.41-1.20 ppm) during a session of 2.5 hours (28).
Kilburn et al. reported 0.24-6.0 mg/m3 (0.2-5 ppm) formaldehyde levels in the
workplace air by area sampling in 10 representative histology laboratories in Los
Angeles, United States, in 1983 (64). The sampling duration was not reported.
The levels were highest during selection of tissue samples for processing.
Kriebel et al. reported formaldehyde exposures in the breathing zone ranging
from 0.59-1.12 mg/m3 (0.49 to 0.93 ppm) with a geometric mean of 0.88 mg/m3
(0.73 ppm) during a clinical anatomy laboratory course at the University of
Massachusetts in the United States (67).
Suruda et al. studied 29 mortician students who were taking a course in
embalming (105). During an 85-day study period, the subjects performed an
average of 62.9 embalmings and had average cumulative formaldehyde exposures
of 14.8 ppm⋅hour, with an average air concentration of 1.68 mg/m3 (1.4 ppm)
during embalming. Since the average time spent embalming was 125 minutes,
formaldehyde exposures calculated as an 8-hour TWA were 0.40 mg/m3 (0.33
ppm).
Mean levels of 8-hour TWA exposure to formaldehyde ranged from about 0.09
mg/m3 (0.08 ppm) in the sawmill and shearing-press departments to 0.39 mg/m3
(0.32 ppm) in the warehouse area of a plywood factory in Italy (10).
Herbert et al. examined the concentrations of formaldehyde from particles and
vapour at five sampling sites in an oriented strand board plant in Canada (54). In
the manufacture they used wood fibre derived from Aspen trees bonded by phenol
formaldehyde. The highest total concentration of formaldehyde was 0.32 mg/m3
(0.27 ppm) recorded at the preheat conveyor. The lowest was 0.08 mg/m3 (0.07
ppm) recorded at the saw line. The samples were collected for 21 hours conti-
nuously at the sites.
5. Kinetics
5.1 Absorption
There are limited human data regarding absorption of formaldehyde through
inhalation. Under normal conditions, absorption is expected to occur in the upper
respiratory tract (nasal passages in obligate nose-breathers; trachea and bronchi in
oral breathers).
From animal data absorption of formaldehyde through the upper respiratory
tract is estimated to be 100% as concluded from the removal of formaldehyde
from the air (59). Detailed studies on the distribution of 14C-formaldehyde in the
rat nasal cavities have confirmed that it is absorbed primarily in the upper
respiratory system.
Another study investigated the retention of formaldehyde gas in the nasal
passages of anaesthetised male rats exposed in a nose-only system to
614C-formaldehyde at 2.4-60 mg/m3 (2-50 ppm) for 30 minutes. More than 93% of
the substance was retained, regardless of airborne concentrations.
Loden performed an in vitro experiment to study the permeability of human
skin to formaldehyde using excised skin in a flow-through diffusion cell (70). The
rate of resorption was determined by measuring the amount of substance found in
the receptor fluid beneath the skin at steady state. The resorption rates of
formaldehyde were: from a concentrated solution of formalin, 319 mg/cm2 per
hour, from a solution of 10% formalin1 in phosphate buffer, 16.7 mg/cm2 per
hour. The fact that formaldehyde induces denaturation of the skin proteins may
have influenced the absorption of the compound.
5.2 Distribution and biotransformation
The IPCS/WHO cited a study on rats, which were exposed by inhalation for 6
hours to 18 mg/m3 (15 ppm) 14C-formaldehyde (59). The distribution of
radioactivity in the tissues was determined. The highest concentrations occurred in
the oesophagus, followed by the kidneys, liver, intestines, and lungs.
There are no data available on the distribution of formaldehyde in the human
body. The mean formaldehyde concentration in human blood after inhalatory
exposure to 2.3 mg/m3 (1.9 ppm) formaldehyde vapour during 40 minutes was
approximately 2.61 ± 0.14 mg/100 ml. However, no statistical difference was
found with pre-exposure levels (59). No increases in blood concentrations of
formaldehyde were detected in rats or human beings exposed to formaldehyde
through inhalation due to rapid metabolism.
The overall metabolism of formaldehyde is summarised in Figure 1. Of
importance are the oxidation of formaldehyde into formic acid and carbon
dioxide, the reaction with glutathione, and the covalent linkage with proteins and
nucleic acids.
proteins and labile methyl groups and
nucleic acids one carbon metabolism
formaldehyde formic acid CO2
urine as sodium salt
Figure 1. Overall metabolism of formaldehyde (65).
                                    
1
 Formalin is defined as 37% formaldehyde in water containing 10-15% methanol
7Formaldehyde is an endogenous metabolite in mammalian systems and it is
rapidly metabolised to formate, which is partially incorporated via normal
metabolic pathways into the one-carbon pool of the body or further oxidised to
carbon dioxide.
5.3 Elimination
After absorption formaldehyde is rapidly metabolised to formate or enters the one-
carbon pool to be incorporated into other molecules. Besides this, there are two
pathways of final elimination, via exhalation or renal elimination. There are no
human data available on the elimination of formaldehyde, but the IPCS/WHO
reported that 81% of subcutaneously administered 14C-formaldehyde to rats was
found again as carbon dioxide and a small amount in choline (59).
5.4 Possibilities for biological monitoring
At present there are no biological monitoring methods available to determine the
magnitude of past exposure to formaldehyde.
There have been a number of cytologic and cytogenetic studies of formaldehyde
exposure in man. These studies examined nasal and buccal cells and blood
lymphocytes of occupationally exposed workers and unexposed control volun-
teers. These studies will be evaluated in the respective chapters.
5.5 Summary
Under normal conditions it is expected that formaldehyde in ambient air is
absorbed through inhalation in the upper respiratory tract. In animals absorption
has been found to be 100%. From in vitro experiments using human skin, it is
estimated that the absorption of a concentrated solution of formalin through the
skin amounted to 319 mg/cm2 per hour.
After inhalation of radioactive formaldehyde by the rat the radioactivity is
distributed in the tissues, with the highest concentration in the oesophagus,
followed by the kidney, liver, intestines, and lung. Retention in the nasal passage
of the rat is estimated at 93% of the dose, regardless of airborne concentrations.
Formaldehyde is an endogenous metabolite in mammalian systems and it is
rapidly metabolised to formate, which is partially incorporated via normal
metabolic pathways into the one-carbon pool of the body or further oxidised to
carbon dioxide. There are two pathways for elimination: via exhalation and via the
kidneys.
There are no biological monitoring methods at present to determine the
magnitude of past exposure to formaldehyde.
86. Effects
6.1 Observation in man
Only a selection of the most adequate human studies from the review of
Paustenbach et al. is discussed in this chapter (92).
6.1.1 Odour
At high concentrations, e.g. 6-12 mg/m3 (5-10 ppm), formaldehyde has a distinct
and pungent odour. The odour of formaldehyde is detectable and/or recognisable
by most individuals at concentrations around 1.2 mg/m3 (1 ppm) (59). The odour
threshold (i.e. the concentration at which a group of observers can detect the
odour in 50% of the presentations) of formaldehyde ranges from 0.06 to 0.22
mg/m3 (0.05-0.18 ppm).
6.1.2 Sensory irritation
For most odorous irritants, the trigeminal nerve has a higher threshold than the
olfactory nerve. However, when the formaldehyde concentration is increased,
sensory irritation is first experienced in the eyes, then the odour is perceived, and
finally nasal irritation occurs (59).
Surveys
Akbar-Khanzadeh et al. studied 34 workers employed in a gross anatomy
laboratory in Toledo, Unites States (3). They were exposed to formaldehyde at
(TWA) concentrations ranging from 0.08 to 3.53 mg/m3 (0.07-2.94 ppm)
(duration of exposure not described). More than 94% of the subjects were exposed
to formaldehyde concentrations exceeding 0.36 mg/m3 (0.3 ppm). By more than
70% of the exposed subjects, irritation of the eyes (88%) and nose (74%) were
reported.
Kriebel et al. investigated students exposed to formaldehyde during a clinical
anatomy laboratory course when dissecting cadavers for 3 hours per week over a
10-week period (67). Formaldehyde exposures in the breathing zone ranged from
0.59-1.12 mg/m3 (0.49-0.93 ppm), with a geometric mean of 0.88 mg/m3 (0.73
ppm). Symptoms of irritation increased strongly during the day, and the effects
were stronger at the beginning than at the end of the semester. The prevalence of
symptoms at the start of the laboratory session ranged from 15% for cough to 46%
for nose irritation. At the end of the session the prevalences were 20 and 67,
respectively. The average increase in symptoms prevalence from beginning to end
of laboratory session was greatest for eye irritation, with an increase of 43%. No
statistical analyses were reported.
Wilhelmsson and Holmström performed a cross-sectional study on 66
employees of a formaldehyde producing plant in Sweden to determine whether
chronic exposure to formaldehyde often causes symptoms by direct irritation
(120). The workers were exposed almost exclusively to formaldehyde. Mean
duration of exposure was 10 years (range 1-36 years). Thirty-six community
9clerks served as a reference group. The exposure level of the exposed group as
measured by personal sampling was between 0.05 to 0.60 mg/m3 (0.04-0.50 ppm)
formaldehyde, with a mean of 0.26 mg/m3 (0.22 ppm). The reference group was
exposed to an average concentration of 0.09 mg/m3 (0.07 ppm) formaldehyde over
the year. From a (not specified) questionnaire, it appeared that 67% of the exposed
group experienced general nasal discomfort compared to 25% of the reference
group (p<0.001). Nasal discomfort strictly connected to the workplace occurred in
53% of the exposed group and in 3% of the reference group (p<0.001). However,
the questionnaire was not published. Therefore, the committees are of the opinion
that this study might only suggest that after long-term occupational exposure (0.26
mg/m3 formaldehyde), more than 50% of the exposed workers complained of
nasal discomfort, which was attributed to their occupation.
Liu et al. studied the irritant effects associated with formaldehyde exposure in
mobile homes in California (69). Week-long integrated formaldehyde concent-
rations were measured in summer (663 mobile homes with 1 394 residents) and
winter (523 mobile homes with 1 096 residents), using passive monitors while the
mobile home residents continued their normal activities. The concentrations
varied from below the detection limit (0.0012 mg/m3) to 0.55 mg/m3. Irritant
effects were found to be significantly associated with formaldehyde exposure after
controlling for age, sex, smoking status, and chronic illnesses. Effects included
complaints of burning/tearing eyes, stinging/burning skin, fatigue, and sleeping
problems in summer and burning/tearing eyes, chest pain, dizziness, sleeping
problems, and sore throat in winter. For the three weekly ranges of formaldehyde
exposure that were distinguished (less than 8.4 mg/m3·hour, between 8.4-14.4
mg/m3·hour, more than 14.4 mg/m3·hour), the percentages of people with
burning/tearing eyes in the summer increased from 13.3% to 17.1% and then to
21.4%. In winter, percentages increased from 10.8% to 14.7% and then to 20.6%.
Controlled human studies
Weber-Tschopp et al. exposed healthy volunteers to increasing concentrations of
formaldehyde from 0.036 to 4.8 mg/m3 (0.03-4 ppm) (116). Thirty-three subjects
were continuously exposed for 35 minutes and 48 subjects were exposed for 1.5
minute. The irritating effects were determined by the eye-blinking rate of the
individuals. The authors found that the irritating effects increased as a function of
the formaldehyde concentration. The irritation threshold of formaldehyde was
placed in the range between 1.2 and 2.4 mg/m3 (1 and 2 ppm). The authors
suggested that adaptation to the irritation occurred after a few minutes in subjects
after prolonged exposure to formaldehyde.
Bender et al. studied eye irritation in groups of volunteers (n= 5-28 per group)
exposed to 0, 0.42, 0.67, 0.84, 1.08 and 1.2 mg/m3 (0, 0.35, 0.56, 0.7, 0.9 and 1.0
ppm) formaldehyde for 6 minutes (12). The authors reported that the subjective
measurements of eye irritation may be affected by a variety of psychological and
physiological factors, such as air flow over the eyes, dust particles, length of sleep
the previous night, etc. In spite of the large variation in response time, there was
still a significant relationship between formaldehyde concentration and time to
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detection of response. The authors concluded that eye irritation occurred at
exposure concentrations of 0.42-1.1 mg/m3 (0.35-0.9 ppm) formaldehyde. The
response was slight until a concentration of 1.2 mg/m3 (1 ppm) was reached.
Andersen and Mølhave conducted a study in which 16 healthy subjects (5
smokers) were exposed to 0.29, 0.48, 0.97 or 1.92 mg/m3 (0.24, 0.4, 0.81 or 1.6
ppm) formaldehyde for 5 hours (4). The purpose of the study was to determine the
concentration at which eye irritation occurred. Nineteen percent of the respon-
dents reported eye irritation at 0.29 mg/m3 (0.24 ppm). Discomfort increased
during the first 2 hours of exposure up to 0.97 mg/m3 (0.81 ppm); then irritation
stabilised for the remaining 3 hours. A decrease in discomfort was observed at
1.92 mg/m3 (1.6 ppm), indicating acclimatisation. After 5 hours of exposure, 38%
of the subjects had no complaints at 1.92 mg/m3 (1.6 ppm), and 63% had no
discomfort at 0.97 mg/m3 (0.81 ppm). This study illustrates the relatively wide
variation in individual susceptibility to irritation from formaldehyde.
6.1.3 Rhinitis
Pazdrak et al. tried to characterise the nature of formaldehyde induced nasal
response consisting of symptoms of rhinitis and changes in nasal lavage fluid (93).
Eleven healthy subjects and 9 patients with specific skin sensitisation were
provoked in an experimental chamber with formaldehyde at a concentration of
0.48 mg/m3 (0.4 ppm) for 2 hours. Nasal lavage was performed prior to and
immediately after provocation, and 4 and 8 hours later. It was found that the
provocation caused transient symptoms of rhinitis and prolonged changes in nasal
washing. There were increases in the relative number of eosinophils, and in
albumin and total protein levels in the nasal fluid, 4 and 8 hours after provocation.
No difference was found between the healthy subjects and patients. These data
confirm the irritant effects of inhaled formaldehyde and might suggest that inhaled
formaldehyde is capable of inducing non-specific inflammatory changes at a
concentration of 0.48 mg/m3 (0.4 ppm).
6.1.4 Effects on pulmonary function in healthy and asthmatic subjects
Witek Jr et al. evaluated the respiratory effects in asthmatics after exposure to
formaldehyde (123). Fifteen asthmatic volunteers were exposed in a double-blind
manner to room air or 2.4 mg/m3 (2 ppm) formaldehyde for 40 minutes. These
exposures were repeated on a separate day during moderate exercise (450
kpm/minutes) for 10 minutes. Pulmonary function was assessed by using partial
and maximal flow volume curves. The following parameters were determined:
vital capacity, residual volume, total lung capacity, forced expiratory volume in
one second (FEV1), forced vital capacity (FVC), peak expiratory flow rate, and
maximal flow at 50% of vital capacity. No significant airway obstruction or
airway resistance was noted in this group during and immediately after exposure.
However, bad odour, sore throat, and eye irritation were common during
exposure, but the symptoms were infrequent afterwards. No delayed broncho-
constriction was detected with measurements of peak expiratory flow.
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The results of this study were substantiated by Sauder et al. (98). In their study
on 9 non-smoking asthmatic volunteers, they also found no significant changes in
the pulmonary function [FVC, FEV1, mean forced expiratory flow during the
middle half of the FVC (25-75%), specific airway conductance or functional
residual capacity] or airway reactivity when the volunteers were exposed to 3.6
mg/m3 (3 ppm) formaldehyde vapour for 3 hours. However, there was a
significant increase in nose and throat irritation at the 30th minute and eye
irritation at the 60th and 180th minutes of exposure.
Harving et al. studied the possible effects of acute formaldehyde exposure on
the lung function of asthmatic subjects. They exposed 15 non-smoking asthmatic
subjects, with documented bronchial hyperresponsiveness, to 0.08, 0.12 or 0.85
mg/m3 formaldehyde for 90 minutes (47). All except one subject required
bronchodilator therapy and none were using methylxanthines or corticosteroids.
Exposure occurred in a climate chamber and the protocol was double blind. No
control group was used in this experiment. Lung function tests were carried out
before the exposure period and repeated near the end. The results showed no
significant changes in the FEV1, functional residual capacity, airway resistance,
specific airway resistance, and flow-volume curves during formaldehyde
exposure. Furthermore, histamine challenge performed immediately after
formaldehyde exposure showed no evidence of changes in bronchial hyper-
reactivity. No late reactions were registered during the first 14-16 hours after
exposure. There was no association of subjective ratings of symptoms, if any, with
increasing exposure. The rating of symptoms did not differ significantly when the
three exposure levels were compared. The results of this study suggest that the
exposure levels of formaldehyde used were of minor, if any, importance in the
emergence of pulmonary symptoms in asthmatic subjects.
Chia et al. examined 150 first-year medical students exposed to formaldehyde
during dissection of cadavers in a gross anatomy laboratory (28). As a reference
group they used 189 third- and fourth-year medical students matched for sex,
ethnic group, and age. The mean concentration of formaldehyde in the area was
0.60 mg/m3 (0.50 ppm) and the mean concentration of personal samples was 0.89
mg/m3 (0.74 ppm). The latter had a range of 0.49 to 1.44 mg/m3 (0.41-1.20 ppm).
No differences were found in FEV1 and FVC among 22 randomly selected male
and female subjects, when the measurements were compared between the first day
after two weeks vacation and after the dissection period. Significant differences,
however, were observed in the exposed group for symptoms of decreased ability
to smell, eye irritation, and dry mouth in comparison with the reference group.
Herbert et al. performed a cross-sectional study on 99 workers employed in the
manufacture of oriented strand board (54). The reference group consisted of 165
unexposed workers from a petroleum industry. Both groups were investigated
using questionnaires, spirometry and skin prick tests to common environmental
antigens. Environmental monitoring showed dust levels with a mean of 0.27
mg/m3. The mass mean aerodynamic diameter of the particles was 2.5 mm. The
concentration of formaldehyde was between 0.08 and 0.32 mg/m3 (0.07-0.27 ppm)
in the strand board factory. Lung function tests showed significant differences
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between strand board workers and workers from the petroleum industry in the
FEV1/FVC ratio and reductions of FEV1 (p=0.044) and FVC (p=0.022) during the
shift work. Also, the strand board workers complained of self-reported asthma and
of lower respiratory tract symptoms significantly more frequent than the oil
workers. The prevalence of atopy did not differ between both groups. Lung
function was significantly better in the strand board workers who had no
symptoms, compared with symptomatic workers. Since the complaints of self-
reported asthma and of lower respiratory tract symptoms by the exposed group
occurred at rather low concentrations of formaldehyde and dusts, the authors
concluded that the effects may have been related to small particles containing
formaldehyde that penetrated deep into the airways.
Horvath et al. surveyed 109 workers (exposed to formaldehyde from 1 to 20
years) for symptoms of respiratory tract irritation (57). Estimates of the exposure
ranged from 0.2 to 3.5 mg/m3 (0.17-2.93 ppm) (mean 0.83 mg/m3 (0.69 ppm)).
The percentage of the exposed workers reporting respiratory irritation was
significantly higher than in the non-exposed group (n=264).
6.1.5 Sensitisation
Respiratory tract sensitisation
Grammer et al. evaluated the immunological response to formaldehyde exposure
in a group of 37 workers in a cross-sectional study (44). The durations of
employment were not reported. Concentrations of formaldehyde in air sampling in
several work areas at various times ranged from 0.004 to 0.087 mg/m3
(0.003-0.073 ppm) as TWAs. The workers were also exposed to phenol and
organic solvents. A clinical assessment included review of a summary of medical
history, physical examination, chest X-ray films, and pulmonary function studies.
Serologic assessment was made with an enzyme linked immunosorbent assay for
IgE and IgG to formaldehyde-human serum albumin. It was found that none of the
workers had IgE or IgG antibodies to formaldehyde-human serum albumin or an
immunologically mediated respiratory or ocular disease caused by formaldehyde.
Thrasher et al. studied four groups of patients with long-term inhalation
exposure to formaldehyde consisting of (1) mobile home residents, (2) office
workers who had worked in a new office building, (3) subjects who had moved
from mobile homes for at least one year, and (4) subjects who had worked in jobs
with possible exposure to formaldehyde (110). All patients in this study had
sought continuous medical attention because of multiple complaints involving the
central nervous system (CNS). They were compared with a group of students who
had been exposed to formaldehyde for 13 hours per week for 28 weeks while
studying anatomy. No measurements of formaldehyde in air were performed.
When compared to the controls it was found that the patients had significantly
higher autoantibodies and antibody titers and B-cell titers to formaldehyde-human
serum albumin.
Sixty-three practising pathologists in Alberta, Canada, were studied regarding
atopy and sensitivity to formaldehyde (97). Serum samples were assayed for total
IgE levels and the presence of IgE with specificity towards formaldehyde.
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Twenty-nine of the subjects (46%) had a history of atopy that was confirmed in 12
by either IgE levels or a positive radio-allergosorbent test. Twenty-nine (46%)
complained of formaldehyde sensitivity. In this study, none of the pathologists
had allergen-specific IgEs directed against formaldehyde, and there was no
evidence of a tendency for atopic subjects to be more prone to sensitivity to
formaldehyde. However, the authors confirmed that this might have been related
to the deliberate reduction in exposure by individuals experiencing adverse
effects.
 A case-report was described by Grammer et al. (43). The subject was a worker
with clinical symptoms compatible with bronchospasm caused by formaldehyde
exposure. An enzyme linked immunosorbent assay showed that the worker had
positive IgE and IgG titers to formaldehyde-human serum albumin. The worker
had a positive intracutaneous test for formaldehyde-human serum albumin. The
cutaneous reactivity could be transferred to a rhesus monkey through the worker’s
serum. The worker had a negative metacholine challenge at 25 mg/ml and
negative formaldehyde inhalation challenges at 0.36, 1.2, 3.6, and 6 mg/m3 (0.3, 1,
3, and 5 ppm) for 20 minutes. The authors concluded that the worker’s symptoms
were probably not caused by immunologically mediated asthma. Based on their
experience, they stated that immunologically mediated asthma caused by
formaldehyde is extremely rare, if it exists at all.
In 1991, Bardana Jr and Montanaro made an extensive review and analysis of
the immunological effects of formaldehyde (11). They concluded that formal-
dehyde is capable of acting as a respiratory irritant. But according to the authors
of the review, there is no consistent evidence indicating that formaldehyde is a
respiratory sensitiser. Formaldehyde does not induce transient or permanent
bronchial hyperreactivity, which has been associated with e.g. exposure to ozone
or nitrogen dioxide. Almost the same conclusions were drawn by IPCS/WHO
(59). They commented that there are a few case-reports of asthma-like symptoms
caused by formaldehyde, but none of these demonstrated a sensitisation effect
(neither Type I nor Type IV) and the symptoms were considered to be due to
irritation.
Garrett et al. studied a group of 148 children (age 7-14), 53 of whom were
asthmatic, in houses in Australia between March 1994 and February 1995 (42).
The mean indoor formaldehyde exposure level was 15.8 mg/m3 and an association
between formaldehyde exposure and atopy [odds ratio (OR) 1.4; 95% confidence
interval (CI): 0.98-2.00] was observed. The committees noted, however, the
potential selection bias in this study.
Skin sensitisation
According to the IPCS/WHO skin sensitisation by formaldehyde has been shown
only by direct skin contact with formaldehyde solutions in concentrations of 20 g/l
(2%) and higher (59). The lowest patch test challenge concentration in an aqueous
solution reported to produce a reaction in sensitised persons was 0.05% formal-
dehyde.
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Flyvholm and Menné interviewed 11 patients with eczema and a positive patch
test to formaldehyde (40). All patients used one or more products containing
formaldehyde or formaldehyde releasers. Sources of exposure were cosmetics and
personal care products, dishwashing liquids, water-based paints, photographic
products etc.
Liden et al. reported absence of specific IgE antibodies in allergic contact
sensitivity to formaldehyde (68). They studied 23 patients with positive
epicutaneous test reactions to formaldehyde, recruited from dermatologic
departments in Sweden. The patients were between 21-74 years old and 19 were
women. The tests had been performed 6 months to 10 years before inclusion in the
study. On re-testing, 15 showed a positive reaction. Eight patients showed atopic
diathesis, and 8 had a history of ongoing atopic dermatitis. In the radio-allergo-
sorbent test only 2 non-atopic patients had specific IgE antibodies to formalde-
hyde. In cellular infiltrates from biopsies of epicutaneous test sites cells reactive
with monoclonal antibodies against IgE were found in positive and in negative
formalin tests, both in atopics and non-atopics, as well as in control biopsies from
non-lesional skin. Double immunofluorescence staining experiments showed that
IgE occurred on Langerhans cells. The proportion of IgE-positive cells correlated
to the level of serum IgE, but not to atopy. These cells were also found in the
epidermis and in the dermis of non-atopic patients. The authors concluded that
this study did not support the hypothesis that specific IgE antibodies are active in
the pathogenesis of contact sensitivity to formaldehyde, neither in atopic nor in
non-atopic patients.
Cronin performed an investigation in the St John Dermatology Center in
London to determine the prevalence of formaldehyde sensitivity and to establish
whether there is a significant correlation between formaldehyde sensitivity and
hand eczema (33). The study spanned 6 years, from 1984 to 1989. In this period a
total of 4 553 men were patch tested with a 1% aqueous solution of formaldehyde.
The prevalence of sensitisation was approximately 2-3% each year. During these
6 years, 98 men (2.2%) were sensitised. During the same period 6 479 women
were patch tested with a 1% aqueous solution of formaldehyde. The prevalence of
sensitisation was remarkably constant at approximately 4% each year. During
these 6 years 235 women (3.6%) showed a positive reaction and 117 women were
primarily sensitised by formaldehyde, of whom 61 (52%) had hand eczema. Of
this group 2% was occupationally exposed and 88% domestic.
In their review Bardane and Montanaro pointed out that the threshold for
induction of delayed hypersensitivity contact dermatitis has not been determined
precisely (11). The frequency of allergic contact dermatitis to formaldehyde was
estimated by the authors to range between 3% and 6% in the general population.
Cross reactivity with other aldehydes has not yet been demonstrated; glutar-
aldehyde does not cross react. Formaldehyde has also been reported to cause
contact urticaria, but the mechanism of action has never been clearly demon-
strated.
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6.1.6 Toxicity due to acute and short-term exposures
No cases of death from formaldehyde inhalation have been published (59).
The IPCS/WHO summarised the clinical features of formaldehyde intoxication
including weakness, headache, abdominal pain, vertigo, anaesthesia, anxiety,
burning sensation in the nose and throat, thirst, clammy skin, central nervous
system depression, coma, convulsions, cyanosis, diarrhoea, dizziness, dysphagia,
irritation and necrosis of mucous membranes and gastrointestinal tract, vomiting,
hoarseness, nausea, pallor, shock, and stupor (59).
Effects on the respiratory system caused by high formaldehyde concentrations
are pneumonia, dyspnoea, wheezing, laryngeal and pulmonary oedema, broncho-
spasm, coughing of frothy fluid, respiratory depression, obstructive tracheo-
bronchitis, laryngeal spasm, and sensation of substernal pressure.
Acute ingestion may cause renal injury (dysuria, anuria, pyuria, and haemat-
uria) and leads to an increase in formate levels in the urine.
6.1.7 Epidemiological studies
Cross-sectional morbidity studies
A summary of cross-sectional morbidity studies of workers occupationally
exposed to formaldehyde is presented in Table 2.
From these studies it may be concluded that symptoms of irritation of the upper
respiratory tract already occurred after acute exposure to levels below 1.2 mg/m3
(1 ppm) formaldehyde. After exposure for a few hours decreases of the FEV1 and
FVC have been observed.
Of interest are the cross-sectional morbidity studies performed by Wilhelmsson
and Holmström (120), Herbert et al. (54), and Boysen et al. (22).
The study by Wilhelmsson and Holmström (120) on 66 workers occupationally
exposed to formaldehyde during formaldehyde production is described in section
6.1.2. Beside irritation, the authors were also interested in whether chronic
exposure affected exposed people through hyperreactivity in atopic persons,
through formaldehyde-induced hyperreactivity in non-atopic persons, or through
immunologically mediated, immediate Type I reactions to formaldehyde itself.
Among the 53% of the exposed workers experiencing nasal discomfort through
hyperreactivity, atopics were not significantly overrepresented. Two workers with
occasional occupational nasal discomfort, and sensitised by long-term inhalation,
had a positive radio-allergosorbent test for formaldehyde. Of the occupationally
exposed group 20% experienced general eye problems. The frequency in the
control group was 0%. Thirty-six percent of the exposed group had dermato-
logical problems such as eczema or itching, while the corresponding frequency
among the control group was 11%. The authors concluded that in certain
circumstances formaldehyde can induce an IgE-mediated Type I reaction in the
nose, but in most cases the annoying nasal symptoms are caused by formaldehyde
induced hyperreactivity, which can cause problems in about 50% of a population
exposed to formaldehyde at an average level of 0.26 mg/m3 (0.22 ppm). Another
interesting finding was that atopics run approximately the same risk of suffering
from this hyperreactivity as non-atopics. However, these results were obtained
16
Ta
bl
e 
2.
 
Cr
os
s-
se
ct
io
na
l m
or
bi
di
ty
 st
ud
ie
s o
f w
or
ke
rs
 o
cc
up
at
io
na
lly
 e
xp
os
ed
 to
 fo
rm
al
de
hy
de
.
Fa
ct
or
y 
or
 p
ro
fe
ss
io
ns
(co
un
try
)
N
um
be
r o
f s
ub
jec
ts
(C
=c
on
tro
ls)
Le
ve
ls 
of
 e
xp
os
ur
e
in
 p
pm
 (m
g/m
3 )
Co
nf
ou
nd
in
g
fa
ct
or
s
Ef
fe
ct
s
R
ef
er
en
ce
A
irp
la
ne
 p
ro
du
ct
io
n
(U
nit
ed
 St
ate
s)
37 (no
 co
ntr
ol 
gro
up
)
0.
00
3-
0.
07
3
(0.
00
4-0
.08
8)
Co
-e
xp
os
ur
e 
to
 p
he
no
l
an
d 
or
ga
ni
c 
so
lv
en
ts
14
 w
or
ke
rs
 w
ith
 ir
rit
an
t s
yn
dr
om
e.
 N
on
e 
of
th
em
 h
ad
 re
sp
ira
to
ry
 o
r o
cu
la
r d
ise
as
e 
th
at
 w
as
im
m
un
ol
og
ic
al
ly
 m
ed
ia
te
d.
(44
)
Pl
yw
oo
d 
fa
ct
or
y
(It
aly
)
15 (C
=1
5, 
ma
tch
ed
 fo
r
ag
e 
an
d 
se
x)
0.
08
-0
.3
2
(0.
09
-0.
39
)
Co
-e
xp
os
ur
e 
to
 w
oo
d
du
sts
(0.
23
-0.
73
 m
g/m
3  
)
H
ig
he
r f
re
qu
en
cy
 o
f m
ic
ro
nu
cl
ea
te
d 
ce
lls
 in
n
as
al
 re
sp
ira
to
ry
 c
el
ls.
 C
hr
on
ic
 in
fla
m
m
at
io
n
o
f t
he
 n
as
al
 m
uc
os
a.
 H
ig
he
r f
re
qu
en
cy
 o
f
sq
ua
m
ou
s m
et
ap
la
sia
 c
el
ls.
(10
)
Fo
rm
al
de
hy
de
pr
od
uc
in
g 
pl
an
t
(S
we
de
n)
66
 (3
6%
 sm
ok
ers
)
(C
=3
6, 
28
%
sm
o
ke
rs
)
0.
04
-0
.5
0
(0.
05
-0.
60
)
m
ea
n
 0
.2
2
(0.
26
)
53
%
 o
f e
xp
os
ed
 g
ro
up
 h
ad
 n
as
al
 d
isc
om
fo
rt
(3%
 in
 co
ntr
ol 
gro
up
). 3
3%
 of
 ex
po
sed
 gr
ou
p
ha
d 
ge
ne
ra
l l
ow
er
 re
sp
ira
to
ry
 tr
ac
t d
isc
om
fo
rt
(C
=1
%)
. 2
0%
 of
 ex
po
sed
 gr
ou
p h
ad
 ey
e
pr
ob
le
m
s (
C=
0%
).
(12
0)
O
rie
nt
ed
 st
ra
nd
bo
ar
d 
m
an
uf
ac
tu
re
(C
an
ad
a)
99 (C
=1
65
)
0.
07
-0
.2
7
(0.
08
-0.
32
)
D
us
t l
ev
el
 0
.2
7 
m
g/
m
3
w
ith
 m
as
s m
ea
n 
ae
ro
-
dy
na
m
ic
 d
ia
m
et
er
 2
.5
 µ
m
Si
gn
ifi
ca
nt
 lo
w
er
 F
EV
1/F
V
C,
 a
nd
 c
ro
ss
-s
hi
ft
re
du
ct
io
n 
of
 F
EV
1 
an
d 
FV
C.
 E
le
va
te
d 
re
po
rts
o
f “
as
th
m
a”
 a
nd
 h
ig
he
r f
re
qu
en
cy
 o
f l
ow
er
re
sp
ira
to
ry
 tr
ac
t s
ym
pt
om
s. 
N
o 
di
ffe
re
nc
e 
in
at
op
y.
(54
)
Pa
pe
r m
ill
(In
dia
)
22 (C
=2
7)
0.
02
5
8-
ho
ur
 T
W
A
(0.
03
)
Ex
po
se
d 
su
bje
cts
 sh
ow
ed
 m
ore
 re
spi
rat
ory
sy
m
pt
om
s a
nd
 c
om
pl
ai
nt
s p
er
ta
in
in
g 
to
ga
str
oi
nt
es
tin
al
, m
us
cu
lo
sk
el
et
al
 a
nd
ca
rd
io
va
sc
ul
ar
 sy
ste
m
s. 
N
o 
di
ffe
re
nc
e 
in
he
m
at
ol
og
y.
(10
2)
17
Ta
bl
e 
2.
 
Co
nt
.
Fa
ct
or
y 
or
 p
ro
fe
ss
io
ns
(co
un
try
)
N
um
be
r o
f s
ub
jec
ts
(C
=c
on
tro
ls)
Le
ve
ls 
of
 e
xp
os
ur
e
in
 p
pm
 (m
g/m
3 )
Co
nf
ou
nd
in
g
fa
ct
or
s
Ef
fe
ct
s
R
ef
er
en
ce
Ch
em
ic
al
 c
om
pa
ny
(N
orw
ay
)
37 (C
=3
7, 
ma
tch
ed
 fo
r
ag
e,
 n
o 
di
ffe
re
nc
e 
in
sm
o
ki
ng
 h
ab
its
)
0.
5 
– 
>2
(0.
6 –
 >2
.4)
Ex
po
se
d 
gr
ou
p 
sh
ow
ed
 m
or
e 
pr
on
ou
nc
ed
m
et
ap
la
sti
c 
al
te
ra
tio
ns
 in
 n
as
al
 m
uc
os
a.
 T
hr
ee
o
f 1
7 
w
or
ke
rs
 e
xp
os
ed
 to
 0
.5
-2
 p
pm
 sh
ow
ed
ep
ith
el
ia
l d
ys
pl
as
ia
.
(22
)
A
na
to
m
y 
la
bo
ra
to
ry
(U
nit
ed
 St
ate
s)
34 (C
=1
2)
al
l w
er
e 
no
n-
sm
ok
er
s
0.
07
-2
.9
4
(0.
08
-3.
53
)
Ex
po
su
re
 to
 fo
rm
-
al
de
hy
de
 a
t l
ea
st
6 
w
ee
ks
.
M
ea
n 
1.
24
 (1
.49
)
Em
ba
lm
in
g 
flu
id
co
n
sis
te
d 
of
 3
6%
fo
rm
al
de
hy
de
,
8.
6 
%
 m
et
ha
no
l a
nd
1.
2%
 p
he
no
l
N
o 
di
ffe
re
nc
e 
in
 b
as
ic
 lu
ng
 fu
nc
tio
ns
 b
et
w
ee
n
bo
th
 g
ro
up
s. 
D
ur
in
g 
sh
ift
 th
er
e 
w
as
 a
 d
ec
re
as
e
o
f F
V
C 
an
d 
FE
V
3.
(3)
H
ist
ol
og
y 
la
bo
ra
to
ry
(U
nit
ed
 St
ate
s)
28
0
al
l w
er
e 
no
n-
sm
ok
er
s
(co
mp
are
d t
o n
orm
al
su
bje
cts
 in
 th
e s
am
e
st
at
e)
0.
2-
1.
9
(0.
24
-2.
28
)
w
ith
 p
ea
ks
 o
f 5
 p
pm
(6)
Co
-e
xp
os
ur
e 
to
ch
lo
ro
fo
rm
, x
yl
en
e
an
d 
to
lu
en
e
Ex
po
se
d 
gr
ou
p 
sh
ow
ed
 st
ee
pe
r r
ed
uc
ed
 v
ita
l
ca
pa
ci
ty
 a
nd
 fl
ow
s f
ro
m
 a
ge
 2
0 
to
 6
0.
(63
)
St
ud
en
ts 
du
rin
g
an
at
om
y 
co
ur
se
(U
nit
ed
 St
ate
s)
24 (no
 co
ntr
ol 
gro
up
)
0.
49
-0
.9
3
(0.
59
-1.
12
)
G
eo
m
. m
ea
n 
0.
73
 (0
.88
)
3 
h/
w
ee
k,
 1
0 
w
ee
ks
In
cr
ea
se
 o
f i
rri
ta
nt
 sy
m
pt
om
s, 
str
on
ge
r i
n 
th
e
be
gi
nn
in
g.
 D
ec
lin
e 
in
 th
e 
pe
ak
 e
xp
ira
to
ry
 fl
ow
ra
te
s 
ov
er
 th
e 
se
m
es
te
r. 
Re
po
rts
 o
f “
as
th
m
a”
an
d 
th
ro
at
 ir
rit
at
io
n.
(67
)
St
ud
en
ts 
an
at
om
y 
cl
as
s
(S
ing
ap
ore
)
15
0
(C
=1
89
, m
atc
he
d f
or
ag
e,
 se
x 
an
d 
et
hn
ic
gr
ou
p
0.
41
-1
.2
0
(0.
49
-1.
44
)
M
ea
n 
0.
74
 (0
.89
)
N
o 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
gr
ou
ps
 in
 F
EV
1 
an
d
FV
C.
 S
ig
ni
fic
an
t d
iff
er
en
ce
s i
n 
sy
m
pt
om
s o
f
de
cr
ea
se
d 
ab
ili
ty
 to
 sm
el
l, 
ey
e 
irr
ita
tio
n,
 th
ro
at
irr
ita
tio
ns
 a
nd
 d
ry
 m
ou
th
.
(28
)
18
from a not published questionnaire and therefore the results are of limited use.
The cross-sectional study by Herbert et al. (54) on workers employed in a
manufacture of oriented strand board is described in section 6.1.4. The workers
showed reduced lung functions and complained more of self-reported asthma and
of lower respiratory tract symptoms compared to the reference group.
Boysen et al. (22) reported on a study on nasal biopsies of 37 workers
occupationally exposed to formaldehyde (chemical company producing
formaldehyde and formaldehyde resin). The workers were exposed for more than
5 years, and they were compared to 37 age-matched controls. The level of
exposure of the exposed group ranged from 0.6 to more than 2.4 mg/m3
formaldehyde. The two groups did not differ as to other environmental influences,
smoking habits, and previous nasal disease. The authors found that the degree of
metaplasia of the nasal mucosa cells was more pronounced among the exposed
workers than among the controls. Three cases of dysplasia out of 17 workers
(18%), all of the squamous type, were observed in the formaldehyde group (zero
cases in the control group). These workers had been exposed daily to formalde-
hyde concentrations ranging from 0.6 mg/m3 to more than 2.4 mg/m3 for more
than 22 years. According to the committees the study, however, is too small to
draw any conclusions. Since only a small area of the nasal mucosa can be
examined histologically, the number of dysplastic lesions found can not be
expected to reflect the real prevalence of dysplasia and therefore the committees
are of the opinion that the real prevalence of dysplasia could even be higher.
Longitudinal/prospective morbidity studies
Nunn et al. followed a group of 164 workers exposed daily to formaldehyde
during the production of urea-formaldehyde resin, together with 129 workers not
exposed to formaldehyde, for 6 years (87). Exposure was classified as high
(TWA more than 2.4 mg/m3), medium (0.72-2.4 mg/m3) or low (0.12-0.6 mg/m3).
Twenty-five % of the workers had high exposure during several periods and 17%
moderate exposure. The annual assessment included lung function testing. The
proportion of self-reported respiratory symptoms was similar in the two groups.
The initial FEV1 was within 0.5 litre of the predicted value (by age and height) in
65% of the exposed and 59% of the unexposed workers, and more than 0.5 litre
below the predicted value in 9% of the exposed and 11% of the unexposed
workers. The mean decline in FEV1 was 42 ml/year in the exposed group and 41
ml/year in the unexposed group. The authors found no association between the
rate of decline and indices of exposure to formaldehyde in the exposed group. In
interpreting these results it is important to assess any possible bias in the conduct
of the study. Workers with adverse respiratory effects from exposure to high
concentrations of formaldehyde may have left employment so that only
“survivors” are included in the study (healthy worker effect).
The effect of low-level exposure to formaldehyde on oral, nasal, and
lymphocytic biological markers were studied prospectively by Suruda et al. in a
group of 29 mortician students who were about to take a course in embalming
(105). During the 85-day study period the subjects performed an average of 69
19
embalmings and had an average cumulative formaldehyde exposure of 14.8
ppm⋅hour, with an average air concentration of 1.7 mg/m3 (1.4 ppm) formal-
dehyde during embalming. The calculated 8-hour TWA was 0.40 mg/m3 (0.33
ppm) on days when embalmings were done. Epithelial cells from the buccal area
of the mouth as well as nasal epithelial cells showed an increase of micronucleus
frequency. In the lymphocytes the micronucleus frequency increased while sister
chromatid exchanges decreased. In this study no control group was used. Each
subject had been used as his or her own control. The study was limited due to the
small number of measurements, other formaldehyde exposures, and due to prior
embalming exposure to formaldehyde of subjects.
Retrospective cohort mortality/morbidity studies
A summary of retrospective cohort mortality studies is presented in Table 3.
Most attention was given to a retrospective cohort mortality study on workers
of 10 formaldehyde-producing or -using facilities in the United States by several
authors, who came to different conclusions (16-19, 74, 75, 103, 104).
The first report of the study was done by Blair et al. (17). This historical cohort
study evaluated the mortality of 26 561 workers, comprising approximately
600 000 person-years. The cohort consisted of all workers first employed before
January 1, 1966. Subjects were traced to January 1, 1980, to determine vital
status. Historical exposure to formaldehyde was estimated by job-related
monitoring data available from participating plants. There were five ranked
categories: (1) trace, (2) <0.12 mg/m3 (<0.1 ppm), (3) 0.12–<0.6 mg/m3 (0.1–<0.5
ppm), (4) 0.6–<2.4 mg/m3 (0.5–<2.0 ppm), and (5) ≥2.4 mg/m3 (≥2.0 ppm). The
standard mortality ratio (SMR) was calculated by comparison with the mortality
rates of the total United States population, local population, and non-exposed
workers. No statistically significant increases occurred of specific cancers. Two
deaths from nasal cancer occurred (both among the exposed), whereas three were
expected. The risk of lung cancer was higher in each exposure category compared
to the non-exposed, due to the lower risk among the non-exposed (in comparison
to the general population). But no trend of increasing lung cancer risk was seen
with cumulative exposure.
In 1987, the authors reported an analysis of the excess mortality from cancers of
the nasopharynx and oropharynx (19). Four of 7 workers with nasopharynx cancer
and 2 of 5 workers with oropharynx cancer occurred in a single plant producing
moulding compounds, which was a dusty operation. The authors concluded that
the patterns for nasopharyngeal cancer suggested that simultaneous exposure to
formaldehyde and particulates may be a risk factor for these tumours. For persons
exposed to particulates, the risk of death from cancer of the nasopharynx
increased with cumulative exposure to formaldehyde from SMR of 192 for 0.6
mg/m3·years (0.5 ppm·years) to 403 for concentrations between 0.6 and 6.6
mg/m3·years (0.5 and 5.5 ppm·years) and to 746 for 6.6 mg/m3·years (5.5
ppm·years). This trend was not significant, however.
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In 1990, the same authors again performed additional analyses to determine
whether the association with formaldehyde may have occurred in a subgroup of
the cohort and/or to identify other occupational risk factors that might have been
involved (18). This report includes only 20 714 white men, the race-sex group that
had an excess of lung cancer. Cumulative exposure was used to assess total dose.
The SMRs and standardised rate ratios (SRRs) were estimated. The authors found
that, in general, the relative risk for lung cancer (both SMRs and SRRs) 20 or
more years after first exposure did not rise with increasing exposure to formal-
dehyde. There was a lack of consistency among the various plants for risk of lung
cancer. Mortality from lung cancer was more strongly associated with exposure to
other substances, including phenol, melanine, urea, and wood dust than with
exposure to formaldehyde.
In 1992, Marsh et al. (75) performed an additional analysis from the same data
collected from Blair et al. (17) by using regression analysis of lung cancer
mortality. There were 242 lung cancer deaths in the cohort of 20 067 white male
workers. SMRs were computed by plant, age, calendar time, and job type for
several time-dependent formaldehyde exposures, including formaldehyde
exposures in the presence of twelve selected co-exposures to other agents. A 1.6-
fold increase in lung cancer risk was found (significant with p<0.01), beginning
approximately 16-20 years after first employment. For workers who were never
co-exposed to any of the ten other agents associated with increased lung cancer
risk, an inverse relation was found between the estimated lung cancer risk ratios
and (cumulative) formaldehyde exposure.
Two years later the same authors (74) performed an enlarged and updated
investigation on one of the plants from the study of Blair et al. (17), which
revealed an excess of nasopharyngeal cancer (4 cases). The cohort consisted of
7 359 workers first employed between the plant start-up in 1941 and 1984. Vital
status was determined on December 31, 1984 for 96% of the cohort and death
certificates were obtained for 93% of 1531 deaths. The statistical analyses focused
on 6 039 white males for the 1945-1984 period. SMRs were calculated based on
both United States and local county death rates. A significantly increased SMR
(550 by local comparison) was found for nasopharyngeal cancer based on the
same 4 cases found earlier. But when the workers were divided into long-term and
short-term employed workers, there were no significant excesses or deficits in the
mortality of long-term workers (n=2 590). In contrast, the short-term workers
(n=3 449) had significantly elevated SMRs for total mortality, ischemic heart
disease, non-malignant respiratory disease, and accidents, and for cancers of the
lung, skin, and CNS. The authors claimed that these increases are difficult to
interpret due to the brief employment of the workers. The results provided little
evidence that the risk of lung cancer and nasopharyngeal cancer was associated
with formaldehyde exposure alone or in combination with particulate or pigment
exposures.
In 1994, Sterling and Weinham (103), using the same data from Blair et al.
(17), compared the more exposed to less exposed workers to compute relative
risks for respiratory and lung cancers using a multiple, log-linear model,
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incorporating factors for job type, cumulative exposure, length of exposure, and
age. Models were fit for all workers, all males, all workers less than 65 years of
age, and for all males less than 65 years of age. The results showed that while
only at high levels of cumulative exposure a significant elevation in relative lung
cancer risk was observed, trend analyses of the coefficients of log-linear models
indicated a significant trend of increasing risk with increasing formaldehyde
exposure.
Shortly after this publication, Blair and Stewart (16) stated that it is unclear why
the results from Sterling and Weinham’s calculations were different from those
performed by others using other approaches which failed to note an exposure-
response gradient. Blair and Stewart noted that apparently the authors had not
considered exposures other than formaldehyde in their analyses and Blair and
Stewart disagreed with their conclusions for several reasons: (1) the exposure-
response gradient was not confirmed by others, (2) the findings differed from
those of other major studies on formaldehyde in several countries, and (3) there
was a stronger linkage between lung cancer and exposures to agents other than
formaldehyde than with formaldehyde itself.
In 1995, Sterling and Weinham replied to the comments (104). They acknow-
ledged that there were a number of crucial procedural differences between Blair et
al. and theirs. Their analysis showed a trend in relative lung and respiratory cancer
risks with increasing cumulative exposure; Blair’s did not. Besides, trend analysis
by Blair et al. was performed on white males and on white male wage earners, and
theirs on all employees and all males. Sterling and Weinham attributed Blair’s
failure to find such a trend to failing to adequately adjust for the “healthy worker
effect”, to restricting their analysis to white males and white male hourly workers
only, and to possible misclassification bias due to their use of less precise
exposure computations.
Hansen and Olsen studied the risk of cancer morbidity in Denmark during
1970-1984 from standardised proportionate incidence ratios (SPIR) among men in
265 companies in which formaldehyde was used (46). The longest employment
had been held since 1964, at least 10 years before diagnosis of cancer. A total of
126 347 men with cancer, born between 1897 and 1964, were identified in the
files of the nationwide Danish Cancer Registry. Individual employment histories
were established for the patients through comprehensive data linkage with
Supplementary Pension Fund. Only 91 182 male cancer cases (72.2%) were found
in the files of the latter, of the rest no record of employment was found. The
results did not show an association between formaldehyde exposure and lung
cancer (SPIR 1.0; 95% CI: 0.9-1.1). However, significantly elevated risks were
found for cancers of the colon (SPIR 1.2; 95% CI: 1.1-1.4), kidney (SPIR 1.3;
95% CI: 1.0-1.6), and sinonasal cavities (SPIR 2.3; 95% CI: 1.3-4.0). For
sinonasal cancer, a relative risk of 3.0 (95% CI: 1.4-5.7) was found among blue
collar workers with no probable exposure to wood dust, the major confounder.
The authors concluded that formaldehyde may increase the risk of sinonasal
cancer in humans. Because of the rarity of nasopharyngeal cancer, it was not
possible to evaluate the risk in this study. According to the committees there are
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some serious shortcomings in this study. First, the exposure classification was
based on the unusual criterion of having been employed at a company that
annually used over one kilogram of formaldehyde per employee. Clearly, only a
small proportion of these employees had been exposed to formaldehyde.
Secondly, job histories were only collected for exposed cases and not for exposed
controls. Thus, an actual comparison of job histories between cases and controls is
not possible. In addition, several of the job histories of the 13 “exposed” cases
provided no evidence for formaldehyde exposure. For instance it is quite unlikely
that a representative of a glue manufacturing company had been exposed to
formaldehyde.
Case-control studies
Partanen et al. performed a nested case-control study in a woodworker cohort in
Finland (91). The cohort consisted of all male production workers who entered
and were employed for at least a year in these plants between January 1944 and
December 1965. Cases (n=136) of respiratory cancers were newly diagnosed
among the cohort members between 1957 and 1982. Three controls (408 in all)
were individually matched to each case according to year of birth. The study size
was determined prior to the start in such a way that an OR of at least 2 would be
detected for respiratory cancer and formaldehyde exposure at an alpha of 0.05
(one-sided) and a power of 0.8. The occupational exposure of the cases ranged
from less than 0.12 to 3.6 mg/m3 (0.1-3 ppm) formaldehyde. The results showed
that the most relevant figure was the OR adjusted for both vital status and
smoking with provision for a latency period of at least 10 years. This OR was 1.4
(95% CI: 0.4-4.1), which did not differ significantly from unity (=1). The OR for
lung cancer was near unity. The number of cases exposed to repeated peak
exposures to formaldehyde was small, and no excess risk was observed. No
significant exposure-response relationship was observed.
Luce et al. conducted a case-control study of cancer of the nose and paranasal
sinuses in France (71). There were 207 histologically confirmed cases, which
were diagnosed between January 1986 and February 1988. The controls were
obtained from two sources, the first being hospital controls consisting of patients
with cancers at other sites, matched for age and sex (control to case ratio 3:2), and
the second coming from a list provided by the cases, matched in sex, age and
residence (n = 233). Occupational exposure to formaldehyde and 14 other
substances was assessed by an occupational hygienist, and the levels of exposure
categorised into low, medium and high. The results indicated that the OR
estimates for formaldehyde exposure and squamous cell carcinomas of nasal
cavities among males, adjusted for exposure to wood dust and glues, did not
significantly differ; the highest OR was below 1.5. The ORs decreased when the
duration and the cumulative levels of exposure increased. This study confirmed
the association between nasal adenocarcinoma and exposure to wood dust. The
authors suggested that interaction between formaldehyde and wood dust is
plausible, since the action of wood dust, by impairing the nasal mucosa, might
enhance the effect of formaldehyde.
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Recently, Andjelkovich et al. reported a nested case-control study in the United
States to identify the determinants of lung cancer mortality in a cohort of 8 147
male foundry workers among whom an excess of lung cancer deaths was observed
previously (7). This study consisted of 220 lung cancer deaths that occurred in this
cohort between 1950 and 1989. Both living and dead controls, matched on race
and attained age, were selected in the ratio 10:1 (n = 2 200). Smoking history was
obtained for about 71% of the study objects. The formaldehyde exposures were
categorised into high, medium, low, and none. The same was done for silica
exposure. The results showed that cigarette smoking was a strong predictor of
lung cancer mortality. Neither exposure to formaldehyde nor silica, nor
employment in any of the six major work areas within the foundry indicated an
association with lung cancer.
A population-based case-control study on cases of bladder cancer was carried
out in Montreal, Canada by Siemiatycki et al. (100). Between 1979 and 1986, 484
persons with pathologically confirmed cases of bladder cancer and 1 879 controls
with cancers at other sites were interviewed, as well as a series of 533 controls of
the general population. The job histories of the subjects were evaluated by a team
of chemist/hygienists for exposure to 294 workplace chemicals, and information
on relevant non-occupational compounds was obtained. One of the substances,
which showed no evidence of an association, was formaldehyde. The estimated
OR for “non-substantial” exposure to formaldehyde was 1.2 (95% CI: 0.9-1.6)
and for “substantial” exposure was 1.2 (95% CI: 0.7-2.0). The results were
adjusted for age, ethnicity, socio-economic status, smoking, coffee, and status of
the respondent.
From these case-control studies the committees conclude that no clear relations
can be found between occupational exposure to formaldehyde and cancer of the
respiratory tract, including cancers of the nose, paranasal sinuses, the lung, and
bladder cancer.
Meta-analysis studies
Three meta-analyses of the carcinogenicity data have been published (15, 31, 90).
The committees decided to use these data as a starting point for the evaluation of
the carcinogenicity and completed with more recent epidemiological studies (if
relevant), which were not discussed in the meta-analysis. The first two meta-
analyses took similar approaches to analysing the data.
Blair et al. performed a meta-analysis of 30 epidemiological studies to evaluate
cancer risks associated with formaldehyde exposure (15). In some studies
excesses were reported for: leukaemia and cancers of the nasal cavities,
nasopharynx, lung, and brain. However, no consistent pattern emerged for any
given cancer across the 30 studies. Inconsistencies among and within studies
impeded assigning formaldehyde a convincing causal role for the excesses of lung
cancer found among industrial workers. The authors divided the exposed groups
into two categories: the professionals, like embalmers, anatomists, pathologists
and funeral professionals, and the industrial workers, subjects employed in the
production of formaldehyde, formaldehyde resins, formaldehyde adhesives,
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paraform, and alcoforms. In the analyses, the observed and expected numbers
were summed for studies of professional and industrial groups separately to create
combined relative risk (CRR) estimates. The summation approach weighs the
risks estimates by study size. The authors found that among the professionals,
significant excesses occurred for leukaemia (CRR 1.6, p<0.05), brain cancer
(CRR 1.5, p<0.05), and colon cancer (CRR 1.3, p<0.05). Fewer deaths from lung
cancer occurred among the professionals (CRR 0.9, p<0.05). In contrast to the
professionals, industrial workers did not show elevated mortality from leukaemia
(CRR 1.1) or brain cancer (CRR 0.9). A small but significant excess of lung
cancer (CRR 1.1, p<0.05) was seen among industrial workers. A non-significant
increase was observed for nasopharyngeal cancer (CRR 1.2), nasal cavity cancer
(CRR 1.1), and bladder cancer (CRR 1.1). The risk of nasal cancer was evaluated
by exposure level or duration. The results showed no exposure-related response
gradient. On the other hand, for nasopharyngeal cancer, the CRR values rose to
2.1 in the high-exposure category (higher than 6.6 mg/m3·year cumulative
exposure), a trend which was significant. The authors concluded that: (1) a causal
association between exposure to formaldehyde and lung cancer could not be
entirely discounted; (2) a causal role for formaldehyde is most probable for
cancers of the nasopharynx; (3) the association with nasal cancer is plausible, but
somehow less persuasive than that for nasopharyngeal cancer; (4) the absence of
excesses for leukaemia and cancers of colon and brain among industrial workers
suggests that the association seen among professional workers may not be due to
formaldehyde.
Partanen (90) also performed a meta-analysis using the same sources as Blair et
al. (15) with some updating. The overlaps between the studies were removed, as
in the earlier study. The aggregated risk ratios were estimated as aggregated
observed-to-expected ratios, and the 95% CIs were set for the risk ratio values.
The main difference between the earlier (original) analysis and the reanalysis was
the selection of the input values. In the reanalysis, of both sinonasal and naso-
pharyngeal cancers, a significant increase was associated with “substantial”
exposure category (risk ratios 1.7 for sinonasal cancers and 2.7 for nasopha-
ryngeal cancers, respectively). Neither an increased risk nor an exposure-response
relation was suggested by the aggregated data for the combined category of
oropharynx, hypopharynx, lip, tongue, salivary glands, and mouth cancer.
Analyses for lung cancer showed a decreased risk for professionals (aggregated
risk ratios = 0.3 and 1.0), for industrial workers the aggregated risk ratio was 1.1
(95% CI: 1.0-1.2). Further analyses for industrial workers alone showed an
aggregated risk ratio of 1.2 for “low-medium” exposure and 1.1 for “substantial”
exposure. The authors concluded that it did remain unlikely that workplace
exposures to formaldehyde pose any substantial lung cancer hazard among
humans. On the other hand, an exposure-response gradient was revealed on
sinonasal cancer; risk in the category of substantial exposure was significantly
elevated. However, according to both committees, in this meta-analysis the
authors did not correct for the unreported studies in which no cases of nasal
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cancers were found. This method must have led to an overestimation of the
overall relative risk for nasopharyngeal cancer.
Collins et al. reported a review of 47 epidemiological studies in which the
carcinogenic risk after occupational exposure to formaldehyde was studied (31).
These 47 studies included studies of industrial cohorts of exposed workers, of
exposed medical specialists, and exposed embalmers case-control studies. After
correction for underreporting a meta relative risk of 1.0 for nasal cancer was
found in the cohort studies and a relative risk of 1.3 for the case-control studies.
The authors concluded that the available studies do not support a causal relation
between formaldehyde exposure and nasopharyngeal cancer. In addition to the
literature review the investigators provide four factors that explain the discrepancy
with the two earlier positive literature reviews. Since this well conducted (more
recent) meta-analysis includes more studies (positive and negative) than the
previous literature reviews and the exposure potential for jobs included in the
general population case-control studies was evaluated, the committees give
preference to the review of Collins et al. over the earlier reviews.
In 2000, Vaughan et al. published a case-control study at five cancer registries
in the Unites States (113). Cases (n=196) with nasopharyngeal cancer diagnosed
between 1987-1993 and controls (n=244) were questioned. The authors concluded
that the results of this study support the hypothesis that occupational exposure to
formaldehyde, but not to wood dust, increases the risk of nasophryngeal cancer
(specific for squamous cell carcinomas). However, no actual exposures to
formaldehyde were measured, the authors used self-reported occupational
histories for assessing exposure concentration. Thus, misclassification was
inevitable.
Finally, the committees conclude that although a small number of studies
produce limited evidence for the association between nasopharyngeal cancer and
exposure to formaldehyde, the overall total body of epidemiological data does not
support a causal relationship for a nasal cancer risk at the experienced exposure
levels.
Genotoxicity
Several studies were identified that described the positive and negative genotoxic
effects after exposure to formaldehyde.
Ying et al. studied the frequency of micronuclei in the cells of nasal mucosa,
oral mucosa, and in lymphocytes of 25 students exposed to formaldehyde (127).
The concentration of formaldehyde was 0.508 ± 0.299 mg/m3. A higher frequency
of micronuclei was observed in nasal and oral exfoliative cells but not in lympho-
cytes. In 1999, Ying et al. evaluated the effects of formaldehyde on peripheral
lymphocytes of 23 non-smoking students (128). No significant difference was
reported between lymphocyte proliferation and sister chromatid exchange.
Vasudeva et al. examined the effect of formaldehyde in the incidence of
chromosome aberrations in peripheral blood lymphocytes of 30 medical students
exposed to concentrations of less than 1.2 mg/m3 (112). There was no difference
in incidence of chromosomal aberrations between the exposed and control group.
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He et al. examined human peripheral lymphocytes of 13 students exposed to
formaldehyde (3.17 mg/m3) for abnormalities (48). Lymphocytes of 10 students of
the same school without formaldehyde exposure served as controls. The micro-
nuclei rate (6.38 ± 2.5, p<0.01), chromosome aberration rate (5.92 ± 2.4, p<0.01),
and sister chromatid exchange rate (3.15 ± 1.57, p<0.05) in the exposed group was
increased.
In conclusion, evidence for genotoxic potential of formaldehyde in humans
exposed to occupational levels is insufficient and conflicting.
6.2 Animal experiments
6.2.1 Sensory irritation
Kane and Alarie exposed Swiss Webster mice for 10 minutes to concentrations of
formaldehyde ranging from 0.62 to 13.4 mg/m3 (0.52-11.2 ppm) to evaluate
sensory irritation after single exposures (61). The concentration associated with a
50% decrease in respiratory rate (RD50) appeared to be 3.6 ± 0.34 mg/m3
(3.0 ± 0.28 ppm).
Wood and Coleman studied the irritant properties of formaldehyde in mice
(n=8) by observing their behaviour (124). The animals were initially trained to
terminate exposure to ammonia by poking their nose five times into a conical
sensor. In this experiment, mice were exposed to a series of concentrations from
1.2 to 12 mg/m3 (1-10 ppm) formaldehyde for a maximum of 60 seconds followed
by a 60 seconds washout period; this cycle was repeated 25 times per session. As
the concentration of formaldehyde increased, the time span after which the
animals terminated their exposure shortened. This study showed that formalde-
hyde was aversive to mice at concentrations, which approximate those at which
humans reported sensory irritation.
6.2.2 Airway reactivity
Adult male Cynomolgus monkeys (n=9) exposed to an average of 3.1 mg/m3 (2.6
ppm) formaldehyde for 10 minutes showed significant pulmonary function
deficits immediately after the challenge (14). The design of this experiment
included a pre-exposure metacholine challenge to determine whether responses to
formaldehyde were associated with pre-existing bronchial hyperreactivity. A
significant increase of the average pulmonary flow resistance was observed 2, 5,
and 10 minutes after formaldehyde challenge.
The hyperreactivity of the respiratory smooth muscle after exposure to
formaldehyde was studied by Swiecichowski et al. (109). Groups of 5-7 guinea
pigs were exposed to (I) 1, 4, 11.3, or 37.3 mg/m3 (0.86, 3.4, 9.4, or 31.1 ppm)
formaldehyde for 2 hours, or to (II) 0.1, 0.4, 0.7 or 1.3 mg/m3 (0.11, 0.31, 0.59 or
1.05 ppm) formaldehyde for 8 hours. The airway reactivity was assessed before
exposure to formaldehyde and 1 and 24 hours after exposure, using in vivo and in
vitro methods. The authors found that the specific pulmonary resistance and
airway reactivity (to infused acetylcholine) increased with increasing form-
aldehyde exposure. Formaldehyde exposure caused bronchoconstriction and
28
hyperreactivity at lower concentrations when exposure was extended from 2 to 8
hours. Exposure to concentrations of formaldehyde higher than 0.37 mg/m3 for 8
hours was sufficient to produce a significant increase in airway reactivity, while
similar effects after 2 hours exposure only occurred at concentrations above 11
mg/m3. Formaldehyde exposure also heightened airway smooth muscle respon-
siveness to acetylcholine or carbachol in vitro. These effects occurred with no
evidence of epithelial damage or inflammation up to 4 days after formaldehyde
exposure. From this study the committees conclude that the no observed adverse
effect level (NOAEL) for airway reactivity in guinea pigs is 0.13 mg/m3 (0.11
ppm) formaldehyde vapour.
6.2.3 Sensitisation
Hilton et al. studied the sensitising property of formaldehyde (56). They reported
that the compound elicited strong positive responses in three independent
methods: the guinea pig maximisation test (n=10), the guinea pig occluded patch
test of Buehler (n=10), and the mouse local lymph node assay (n=4). In contrast,
formaldehyde was negative in the mouse IgE test (n=6), which is a novel
predictive test method for assessment of respiratory sensitisation potential. The
authors concluded that, although formaldehyde is a potent contact allergen, it
lacks a significant potential to cause sensitisation of the respiratory tract.
Boman et al. (21) studied the potency of contact allergens, including formal-
dehyde, by using the guinea pig maximisation test (21). For each chemical five
groups of 5 animals each were treated intradermally with concentrations per group
reduced with increments of a factor three from the highest concentration that
could be applied intradermally. Two of the five groups were treated topically with
the highest non-irritating concentration and the three other groups with a 100
times lower concentration. All groups were challenged and re-challenged with the
highest non-irritating concentration. For each chemical a vehicle control group
was included for comparison. Measurements were performed in two different
laboratories. A highly significant dose response relationship was obtained and the
curves were similar at both laboratories and corresponded well with earlier
reported test results supporting that multidose design gives reproducible results.
6.2.4 Acute cytotoxic effects on nasal epithelium
In vitro experiments have been performed by Colizzo et al. to study the alterations
of specific ciliated epithelial cell surface components after exposure to formal-
dehyde levels, which decreased respiratory ciliary function (30). In this experi-
ment, bovine trachea was exposed to 0, 16, 33, and 66 mg formaldehyde per cm2
epithelial surface for 30 minutes. The results showed that the axoneme proteins
(i.e. part of the cilia) decreased with increased formaldehyde concentrations and
the biotinylated proteins proportionally increased. Membrane fractions showed
little change in protein. The data suggest that increasing formaldehyde exposure
reduced both extractable ciliary axonemes and detergent-soluble surface
components.
29
Bhalla et al. investigated the distribution of epithelial cells over the turbinates in
the rat nasal cavity and their injury following exposure to formaldehyde in a nose-
only manner (13). Rats were exposed to either purified air or to 12 mg/m3 (10
ppm) formaldehyde for a period of 4 hours. Changes were seen in the various
regions of the turbinates in the form of ciliary destruction and cell separation
(especially in the naso- and maxilloturbinates), cellular swelling (throughout the
turbinate), mucous release by the goblet cells (in the naso turbinate), and in some
cases pores on the cell surface or between adjacent cells (evident in the meates).
The authors concluded that the degree of deleterious effects of formaldehyde on
the nasal epithelia of rats is dependent upon cell type and location.
6.2.5 Toxicity during short-term exposure
Major short-term inhalation toxicity studies of formaldehyde in experimental
animals are summarised in Table 4.
The critical effects of short-term exposure to airborne formaldehyde in
experimental animals are damage to and increased proliferation of the nasal
epithelium. The histopathological changes range from slight hyperplasia and
squamous cell metaplasia of the ciliated and non-ciliated respiratory epithelium in
specific areas (found at low effective exposure concentrations, i.e. 2.4-3.6 mg/m3)
to severe rhinitis, necrosis, and extensive hyper/metaplasia of major portions of
the nasal epithelium (found at exposure concentrations of about 7.2 mg/m3 and
higher). Substantial increases in epithelial cell turnover rates occur in rats at
exposure concentrations of 7.2 mg/m3 and higher. Marginally and only transiently
increased cell turnover rates have occasionally been found at levels of 0.6-2.4
mg/m3.
Table 4 shows that the majority of NOAELs are between 1.2 and 2.4 mg/m3
(1-2 ppm). Table 4 also reveals that in all studies with a NOAEL of 1.2 mg/m3
(1 ppm) the lowest observed adverse effect level (LOAEL) is higher than 2.4
mg/m3 (2 ppm), indicating a steep dose-response relation (it is possible that in
these studies a NOAEL of 2.4 mg/m3 might have been obtained if this exposure
concentration would have been included in these experiments). However,
occasionally (107, 108, 129) increased cell proliferation has been found at
exposure levels of 0.6 or 1.2 mg/m3 (0.5 or 1 ppm), while the findings of
Woutersen et al. (125) turned out to be inconclusive with respect to 1.2 mg/m3
(1 ppm) being a NOAEL or a LOAEL.
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6.2.6 Toxicity due to long-term exposure and carcinogenicity
Major long-term inhalation toxicity and/or carcinogenicity studies in rats and mice
are summarised in Table 5.
Critical effects of long-term inhalation exposure to formaldehyde include
inflammatory, degenerative and regenerative changes of the nasal mucosa, and
squamous cell carcinomas of the nasal respiratory epithelium. The non-neoplastic
nasal changes range from a minimal degree of hyperplasia and squamous cell
metaplasia of the nasal respiratory epithelium (occasionally seen at concentrations
of approximately 2.4 mg/m3 or lower) to rhinitis, necrosis and extensive restora-
tive hyperplasia and metaplasia of the nasal respiratory epithelium invariably seen
at concentrations of about 7.2 to 18 mg/m3 (6-15 ppm). High incidences of
squamous cell carcinomas have been found in rats at exposure levels of 12 mg/m3
(10 ppm) or higher.
In most long-term studies, a NOAEL of 1.2 or 2.4 mg/m3 have been reported
(Table 5). However, in one long-term study in rats 2.4 mg/m3 (2 ppm) appeared to
be a LOAEL (62) and in another long-term rat study a LOAEL as low as 0.36
mg/m3 (0.3 ppm) was reported (60).
6.2.7 Genotoxicity
The mutagenic properties of formaldehyde have been investigated in many test
systems. A summary as presented by the International Agency for Research on
Cancer (IARC) and WHO is shown in Appendix 2 (58).
After the appearance of the IARC/WHO document (58), more data on the
genotoxicity of formaldehyde have been published. Vock et al. studied the
induction of DNA double-strand breaks in cultured human lung epithelial cells by
pulse-field gel electrophoresis, and the viability was evaluated by the MTT
(dimethylthiazol-diphenyltetrazolium bromide) cytotoxicity test (115). They
reported induction of DNA double-strand breaks by formaldehyde when cell
viability was reduced to less than 60% of the control values, indicating that DNA
double-strand breaks were the consequence of extragenomic damage and viability
loss.
Merk and Speit studied formaldehyde induced DNA-protein cross-links in V79
Chinese hamster cells (77). They observed that formaldehyde, parallel to the
induction of cytotoxicity, induced significant numbers of DNA-protein cross-
links, sister chromatid exchanges, and micronuclei in the same range of
concentrations. In contrast, treatment of V79 cells with formaldehyde did not
induce gene mutations in the HPRT test, even after variations of the treatment
protocol. The authors concluded that formaldehyde induced DNA-protein cross-
links seem to be related to cytotoxicity and clastogenicity, but do not lead to the
formation of gene mutations in mammalian cells.
In an in vivo experiment Casanova et al. reported covalent binding of
formaldehyde to DNA in the respiratory tract of rhesus monkeys (25). The DNA-
protein cross-links were formed after exposure by inhalation (head only) to 0.8,
2.4 or 7.2 mg/m3 (0.7, 2 or 6 ppm) formaldehyde for 6 hours (n=3 per group).
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Odeigah performed two short-term in vivo mutagenicity tests (sperm head
abnormality and dominant lethal mutation assays) in isogenic strains of albino rats
(88). Five daily intraperitoneal injections of formaldehyde resulted in a statisti-
cally significant increase of sperm head abnormalities at doses of 0.125-0.500
mg/kg body weight. The frequency of dominant lethal mutations in female rats
sired by males exposed to formaldehyde was significantly higher than in the
control group.
In summary, no adequate data are available on genetic effects of formaldehyde
in humans. Formaldehyde is comprehensively genotoxic in a variety of experi-
mental systems, ranging from bacteria to rodents. Formaldehyde given by
inhalation or gavage to rats in vivo induced chromosomal aberrations in lung cells,
micronuclei in the gastrointestinal tract, and sperm-head anomalies. Formalde-
hyde induced DNA-protein cross-links, DNA single-strand breaks, chromosomal
aberrations, sister chromatid exchanges, and gene mutations in human cells in
vitro. It induced cell transformation, chromosomal aberrations, sister chromatid
exchanges, DNA strand breaks, DNA-protein cross-links and gene mutations in
rodent cells in vitro. Administration of formaldehyde to Drosophila melanogaster
in the diet induced lethal and visible mutations, deficiencies, duplications,
inversions, translocations, and crossing-over in spermatogonia. Formaldehyde
induced mutations, gene conversion, DNA strand breaks and DNA-protein cross-
links in fungi, and mutations and DNA damage in bacteria. Inhalation of formal-
dehyde leads to formation of DNA-protein cross-links in the nasal respiratory
mucosa of rats and monkeys. The formation of DNA-protein cross-links is a
sublinear function of the formaldehyde concentration in inhaled air from 0.86 to
18.4 mg/m3 (0.71-15.27 ppm), and the yield of DNA-protein cross-links at a given
inhaled concentration is approximately an order of magnitude lower in monkeys
than in rats. There is no detectable accumulation of DNA-protein cross-links
during repeated exposures.
6.2.8 Mechanism of formaldehyde nasal carcinogenesis
From the above data it is clear that formaldehyde is a highly cytotoxic, genotoxic
carcinogen capable of inducing nasal carcinomas in rats and possibly in mice. The
nasal toxicity of formaldehyde is characterised by inhibition of mucociliary
function (83), reaction with small proteins present in nasal mucus (20), reaction
with glutathione followed by detoxification by formaldehyde dehydrogenase (53),
and, when biotransformation is overwhelmed or even inactivated, rhinitis,
degeneration and necrosis followed by regenerative hyperplasia and metaplasia of
the respiratory epithelium (82, 108). These distinct toxic effects have been
invariably found in rats after short- and long-term exposure to concentrations of
about 2.4 mg/m3 (2 ppm) and higher (8, 62, 81, 83, 99, 125, 126).
Formaldehyde appears to be a direct-acting genotoxicant capable of inducing
DNA-protein cross-links in nasal respiratory epithelium of experimental animals
following inhalation exposure (“local genotoxicity”) (72). Cross-linking of DNA
with proteins might be expected to lead to DNA damage during cell replication,
and potential mechanisms for such effects have been reviewed by Heck et al. (51).
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A series of studies has clearly demonstrated a strong deviation from linearity of
the formation of DNA-protein cross-links in the nasal epithelium of rats (23, 50,
52). One of the reasons for this non-linearity is inactivation of formaldehyde by
glutathione, which apparently is much more effective at low (1.2-2.4 mg/m3) than
at high (7.2-18 mg/m3) formaldehyde concentrations (51, 52).
High incidences of nasal carcinomas have been found in rats following long-
term exposure to concentrations of 12 mg/m3 (10 ppm) or higher (60, 62, 81, 99).
These tumour data and the aforementioned toxicity data demonstrate that
exposure levels causing nasal tumours also cause rhinitis, necrosis and epithelial
hyperplasia and metaplasia of the nasal mucosa. Moreover, in a study on the more
precise localisation of the formaldehyde induced nasal tumours in rats, Morgan et
al. showed that tumours invariably occurred at locations of mucociliary inhibition,
and epithelial hyperplasia and metaplasia (84). The dose-response curve for nasal
tumours is very steep and extremely non-linear, while its shape appears to corres-
pond with that of the dose-response curves for DNA-protein cross-links, inhibition
of the mucociliary function, increased cell proliferation, and hyperplasia and
metaplasia of the nasal respiratory epithelium. Obviously, an association exists
between the cytotoxic, genotoxic, and carcinogenic effects (82). In other words,
the steep non-linear dose-response curve for nasal tumours – indicating a more
than proportionate decrease in cancer incidence at low concentrations – is most
probably due to the fact that defence mechanisms of the nose (mucociliary
clearance, detoxification by dehydrogenase, DNA repair) are very effective at low
concentrations, but can be overwhelmed and inactivated at high concentrations;
consequently, cell and tissue damage and finally tumours occur at high concen-
trations only.
These data and considerations suggest that the induction of nasal carcinomas by
formaldehyde requires long-term exposure to levels that cause considerable
damage to the nasal epithelium followed by restorative hyperplasia. This
increased cell replication and subsequent cycles of DNA synthesis, provoked by
long-term exposure to formaldehyde, may strongly enhance the likelihood of
relevant DNA damage, and moreover, may strongly enhance the progression of
initiated/preneoplastic cells to cancer. This also means that formaldehyde in
concentrations not leading to tissue damage most probably cannot act as a
complete carcinogen (causing initiation, promotion, and progression), and as a
result is very unlikely to induce cancer by itself. Therefore, it is concluded that
cytotoxic effects of formaldehyde play a highly significant, if not an essential role,
in the formation of nasal tumours by formaldehyde. This conclusion is strongly
supported by the results of a long-term inhalation study, in which male rats with a
severely damaged or undamaged nasal mucosa were exposed to 0, 0.12, 1.2 or 12
mg/m3 (0, 0.1, 1.0 or 10 ppm) formaldehyde for 6 hours/day, 5 days/week, during
either 28 months or 3 months followed by a non-exposure, observation period of
25 months (126). The damage to the nasal mucosa was induced by bilateral
intranasal electrocoagulation. Treatment related nasal tumours (squamous cell
carcinomas) only occurred in the 12 mg/m3 group of rats with a damaged nasal
mucosa and exposed to formaldehyde for 28 months. Obviously, severe damage to
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the nasal mucosa in combination with prolonged exposure to a relatively high
cytotoxic concentration of formaldehyde leads to tumour formation. In this study,
12 mg/m3 formaldehyde induced extensive and severe hyperplasia and metaplasia
in the intact nasal mucosa, but no tumours. Clearly, for tumour formation
“drastic” conditions seem to be required: severe damage plus a relatively high
concentration (dose) of formaldehyde (38, 39).
6.2.9 Reproductive toxicity
In 1987, DECOS concluded in its previous document on formaldehyde that, based
on studies available at that time, formaldehyde had not been demonstrated to
cause adverse reproductive outcomes, even though foetotoxicity but not teratoge-
nic effects had been observed, following administration of high doses of a known
precursor of formaldehyde (hexamethylene tetramine). Therefore, it was
suggested that additional studies in this field should be conducted. In 1989, the
IPCS/WHO concluded that animal experiments did not show any evidence of the
embryo, it being unusually sensitive to formaldehyde, and there was no informa-
tion to show that formaldehyde was teratogenic in rodents when administered
orally or applied dermally in non-toxic amounts to the dams (59). Furthermore,
the data did not provide any evidence indicating that formaldehyde caused terata
at exposure concentrations that were not toxic for the adult.
Saillenfait et al. studied the reproductive toxicity of formaldehyde in Sprague-
Dawley rats (96). Groups of 25 pregnant rats were exposed by inhalation to 0, 6,
12, 24 or 48 mg/m3 (0, 5, 10, 20 or 40 ppm) formaldehyde, 6 hours/day, from day
6 to 20 of gestation. No effect was found on embryonic or foetal lethality, nor
significant alterations in the external, visceral or skeletal appearances of the
foetuses. Significant concentration related reduction of foetal body weight
occurred at 24 and 48 mg/m3 (20 and 40 ppm). Maternal toxicity was observed at
48 mg/m3 (40 ppm), as indicated by reduction of body weight and body weight
gain.
Martin exposed groups of 25 mated rats by (whole-body) inhalation to 2.4, 6.0
or 12 mg/m3 (2, 5 or 10 ppm) formaldehyde 6 hours/day, from day 6 to day 15 of
gestation (76). Two control groups were used. The pregnancy rate in all groups
was at least 80%. At the highest dose (12 mg/m3) there was a significant decrease
in maternal food consumption and body weight gain. Pregnancy parameters,
including numbers of corpora lutea, implantation sites, live foetuses and
resorptions, foetal weights, sex ratios, and preimplantation and postimplantation
losses were unaffected by the treatment. The overall incidences of litters and
foetuses with major malformations, minor external and visceral anomalies, and
minor skeletal anomalies were not affected by treatment with formaldehyde.
There was no evidence of maternal toxicity at 2.4 and 6 mg/m3 (2 and 5 ppm)
exposure levels. At the 6 and 12 mg/m3 (5 and 10 ppm) dose levels, an apparently
significant concentration related decrease in ossification was detected in the foetal
bones of the pelvic girdle, which was associated with larger litter sizes with
decreased foetal weights in both these groups. Also the slightly lower foetal
weights were considered to be due to the larger litter sizes.
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Recently, Majumber and Kumar reported inhibitory effects of formaldehyde on
the reproductive system of male rats (73). In their experiment, adult male rats
were treated intraperitoneally with formaldehyde at a dose of 10 mg/kg body
weight per day given for 30 days. After the exposure period they found a fall in
tissue protein contents of the epididymis and prostate, while these were not
affected in testes and seminal vesicles. On the other hand, the DNA content had
significantly decreased only in the testes and prostate of treated rats compared to
control rats. The sperm count had decreased by 50% in treated rats. The sperm
viability was also significantly affected and only 30% of viable sperms in the
treated group were motile as compared to 86% in the control group. The authors
also performed an in vitro study in which equal volumes of sperm suspension of
normal rats and different concentrations of formaldehyde were mixed and
incubated at ambient temperature for different time intervals. In this study, 80%
sperms were viable over a period of 1 hour in the control group. At concentrations
of 5 ng/ml formaldehyde only 50% spermatozoa were viable over a period of 30
minutes. At 500 ng/ml formaldehyde 50% spermatozoa were viable over a period
of 6 minutes and at 2.5 mg/ml the effect was profound and instantaneous, and
sperm viability dropped to zero within 10 minutes. Clearly, direct contact of high
concentrations of formaldehyde with sperm affected sperm viability.
From the data the committees conclude that there is no evidence that formal-
dehyde may induce teratogenicity or may affect reproduction by inhalation
exposure.
6.2.10 Other studies
Vargova et al. studied the immunotoxicity of formaldehyde in male rats (111).
The animals were exposed to doses of 0, 20, 40, and 80 mg/kg body weight per
day by oral administration (gastric tube) for 28 days. The body weights of rats
exposed to the highest dose were slightly decreased. The lymph node weights
were significantly increased, but the cellularity of lymphoid organs was not
influenced after 28 days of exposure to formaldehyde. There was a dose
dependent reduction of antibody response (IgG and IgM) at doses of 20, 40, and
80 mg/kg body weight per day. However, there was no significant reduction of the
spleen cells producing IgM antibodies in exposed rats. The hepatocytes of the
exposed animals showed increased cytoplasmic vacuolisation. Histochemistry
revealed narrowing of the thymus-dependent zone in the spleen.
6.3 Summary
The odour threshold of formaldehyde varies from 0.06 to 0.22 mg/m3 (0.05-0.18
ppm) (59).
6.3.1 Human studies
Sensory irritation
Sensory irritation in man is first (at low concentrations) experienced in the eyes,
then (at higher concentrations) the odour of formaldehyde is perceived, and finally
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nasal and throat irritation occur (59). After long-term occupational exposure to an
average concentration of 0.26 mg/m3 (0.22 ppm) formaldehyde (range 0.05-0.6
mg/m3) more than 50% of the workers complained of nasal discomfort (120).
However, in this (not well controlled) study the questionnaire used was not
published. From cross-sectional morbidity studies it appeared that symptoms of
irritation of the upper respiratory tract may occur after acute exposure to formal-
dehyde levels below 1.2 mg/m3 (1 ppm) (28, 102, 120). Also from controlled
studies in volunteers it appeared that at exposure levels for a short period lower
than 1.2 mg/m3 (1 ppm) sensory irritation may still occur in a substantial
percentage of exposed individuals (4, 12). In one study (4), 19% of the exposed
persons reported eye irritation at an exposure level of 0.29 mg/m3 (0.24 ppm).
Rhinitis
Transient rhinitis has been found in volunteers exposed to 0.48 mg/m3 (0.4 ppm)
formaldehyde for 2 hours (93). A cross-sectional study on workers exposed to
formaldehyde levels between 0.6 and 2.4 mg/m3 (0.5-2 ppm) for more than 22
years revealed that 3 of 37 workers (18%) showed epithelial dysplasia in nasal
biopsies; in all 3 cases the dysplasia was of the squamous type (22).
Pulmonary function
No changes in pulmonary function have been found in humans exposed to
formaldehyde concentrations up to 3.6 mg/m3 (3 ppm) (47, 98, 123).
Sensitisation
There is no consistent evidence of formaldehyde being capable of sensitising the
respiratory tract. Under certain circumstances formaldehyde induced an IgE-
mediated Type I reaction in the nose, but in most cases the annoying nasal
symptoms were caused by formaldehyde induced hyperreactivity (120). An
interesting finding was that atopics run approximately the same risk of suffering
from this hyperreactivity as non-atopics (120). Formaldehyde did not induce
transient or permanent bronchial hyperreactivity (11). Symptoms of the lower
respiratory tract, like decreases of lung function parameters, were suggested to be
related to exposure of workers to respirable particles containing formaldehyde
penetrating deep into the airways (54).
Skin sensitisation by formaldehyde has been shown only by direct skin contact
with formaldehyde solutions in concentrations higher than 2% (59). The threshold
for induction of delayed hypersensitivity contact dermatitis has not been deter-
mined precisely. Formaldehyde induced allergic contact dermatitis has been
estimated to occur in 3 to 6% of the population. Formaldehyde has also been
reported to cause contact urticaria, but the mechanism is unknown (11).
Carcinogenic effects
An extensive retrospective cohort mortality study consisting of 26 561 workers
from 10 formaldehyde-producing or -using facilities in the United States showed
no statistically significant excess for specific cancers (17). There was no trend of
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rising lung cancer risk with increasing levels of cumulative exposure to
formaldehyde. Further analysis showed that 4 of 7 workers with nasopharynx
cancer and 2 of 5 workers with oropharynx cancer occurred in a single plant
producing moulding compounds, which was a dusty operation (19). The authors
suggested that simultaneous exposure to formaldehyde and particulates may be a
risk factor for these tumours. Using the same data, other authors calculated there
was a 1.6-fold increase in lung cancer risk beginning approximately 16-20 years
after first employment (75). For workers who were never co-exposed to any of the
ten substances associated with increased lung cancer risk, the cumulative
formaldehyde exposure was inversely related with the estimated lung cancer risk
ratios. An update of the investigation by the same authors provided little evidence
that the risk of lung cancer and nasopharyngeal cancer was associated either with
formaldehyde exposure alone or in combination with particulate or pigment
exposures (74). At the same time, other authors using a different statistical
technique on the same data concluded that only high levels of cumulative
exposure showed a significant elevation in relative lung cancer risk (103). Trend
analysis indicated a significant trend of increasing risk of lung cancer and
respiratory cancer with increasing formaldehyde exposure.
These results have been strongly opposed by the original investigators (16) who
commented that Sterling et al. (103) apparently had not considered exposures
other than formaldehyde in their analysis. Differences in the outcome might have
been attributable to differences in the target population confounded by the healthy
worker effect (104).
A cancer morbidity study showed that formaldehyde may increase the risk for
sinonasal cancer in humans (46). Because of the rarity of nasopharyngeal cancer,
it was not possible to evaluate the risks. There were some serious shortcomings in
this study. Various case-control studies have been performed using end-points as:
respiratory cancer, cancer of the nose and paranasal sinuses, lung cancer, and
bladder cancer. In these studies no firm relationships could be found between
occupational exposure to formaldehyde and these cancers.
A meta-analysis of 30 epidemiological studies indicated no exposure-related
response gradient for CRR on nasal cancer (15). On the other hand, on
nasopharyngeal cancer the CRR value rose to 2.1 in the highest exposure
category; the trend was significant. The results of this study were substantiated by
another meta-analysis (90). However, in this meta-analysis the authors did not
correct for the unreported studies in which no cases of nasal cancers were found.
It is likely that this may have caused an overestimation of the true relative risk. In
a recent meta-analysis of 47 epidemiological studies a correction for underrepor-
ting was made (31). Relative risks for nasal cancers in cohort and case-control
studies were 1.0 and 1.3, respectively. The authors concluded that these studies do
not support a causal relation between formaldehyde exposure and nasopharyngeal
cancer.
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6.3.2 Animal studies
Sensitisation
For formaldehyde a 10-minutes RD50 in mice of 3.6 ± 0.3 mg/m3 (3.0 ± 0.28 ppm)
has been reported (61).
Studies in mice and guinea pigs produced no evidence of formaldehyde being a
respiratory tract sensitiser (56).
Formaldehyde has been shown to be a contact sensitiser (21, 56).
Short-term exposure
The critical effects of short-term exposure to airborne formaldehyde in experi-
mental animals are damage to and increased proliferation of the nasal epithelium.
The histopathological changes range from slight hyperplasia and squamous cell
metaplasia of the ciliated and non-ciliated respiratory epithelium in specific areas,
found at low effective exposure concentrations, i.e. 2.4-3.6 mg/m3 (2-3 ppm), to
severe rhinitis, necrosis and extensive hyperplasia and metaplasia of major
portions of the nasal epithelium, found at exposure concentrations of about 7.2
mg/m3 (6 ppm) and higher (8, 24, 26, 79, 80, 83, 95, 121, 122, 125, 129).
Substantial increases in epithelial cell turnover rates occur in rats at exposure
concentrations of 7.2 mg/m3 (6 ppm) and higher (24, 79, 80, 107, 108). The
majority of NOAELs found in these short-term studies are 1.2 or 2.4 mg/m3 (1 or
2 ppm). In all studies with a NOAEL of 1.2 mg/m3 (1 ppm) the LOAEL was
higher than 2.4 mg/m3 (2 ppm), indicating the possibility that also in these studies
a NOAEL of 2.4 mg/m3 might have been obtained if indeed this exposure level
would have been included in these experiments. However, occasionally
(marginally and transiently) increased cell proliferation has been found at
exposure levels of 0.6 or 1.2 mg/m3 (0.5 or 1 ppm) (107, 108, 129), while the
histopathological changes observed by Woutersen et al. turned out to be
inconclusive with respect to 1.2 mg/m3 (1 ppm) being a NOAEL or a LOAEL
(125).
Long-term exposure
Critical effects of long-term inhalation exposure to formaldehyde include
inflammatory, degenerative and regenerative changes of the nasal mucosa, and
squamous cell carcinomas of the nasal respiratory epithelium. The non-neoplastic
nasal changes range from a minimal degree of hyperplasia and squamous cell
metaplasia of the nasal respiratory epithelium (occasionally seen at concentrations
of approximately 2.4 mg/m3 (2 ppm) or lower) to rhinitis, necrosis and extensive
restorative hyperplasia and metaplasia of the nasal respiratory epithelium
invariably seen at concentrations of about 7.2 to 18 mg/m3 (6-15 ppm).
High incidences of squamous cell carcinomas have been found in rats at
exposure levels of 12 mg/m3 (10 ppm) or higher (60, 62, 81, 99). In most long-
term studies, a NOAEL of 1.2 or 2.4 mg/m3 have been reported. However, in one
long-term study in rats 2.4 mg/m3 (2 ppm) appeared to be a LOAEL (62) and in
another long-term rat study a LOAEL of 0.36 mg/m3 (0.3 ppm) was reported (60).
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Genotoxicity
No adequate data were available on genetic effects of formaldehyde in humans.
Formaldehyde has been investigated for genotoxic properties in many test systems
(58). It is comprehensively genotoxic in a variety of experimental systems,
ranging from bacteria to rodents in vivo. Formaldehyde given by inhalation or
gavage to rats induced chromosomal aberrations in lung cells, micronuclei in
gastro-intestinal tract cells, and sperm-head anomalies. Inhalation of formal-
dehyde leads to formation of DNA-protein cross-links in the nasal respiratory
epithelium of rats and monkeys. The formation of DNA-protein cross-links is a
sub-linear function of the formaldehyde concentration in inhaled air from 0.86 to
18.4 mg/m3 (0.71-15.3 ppm), and the yield of DNA-protein cross-links at a given
inhaled concentration is approximately an order of magnitude lower in monkeys
than in rats. There is no detectable accumulation of DNA-protein cross-links
during repeated exposures (58). In V79 Chinese hamster cells, formaldehyde
induced DNA-protein cross-links, sister chromatid exchanges, and micronuclei,
but no gene mutations, in concentrations similar to those inducing cytotoxicity,
suggesting that formaldehyde induced DNA-protein cross-links are related to
cytotoxicity and clastogenicity (77). In cultured human lung epithelial cells, DNA
double-strand breaks were induced by formaldehyde only when cell viability was
reduced to 60%, indicating that the double-strand breaks were caused by
extragenomic damage and viability loss (115). Recio suggested that the nasal
inflammation and proliferation induced by formaldehyde exposure may contribute
to the induction of genetic alterations through a variety of mechanisms including
generation of reactive oxygen species, alterations in nucleotide pools, free radical
formation, and clonal expansion with further mutation of genetically altered cells
(94).
With respect to the mechanism underlying the nasal carcinogenicity of
formaldehyde in rats, there is a large body of data suggesting an association
between the cytotoxic, genotoxic, and carcinogenic effects of formaldehyde (29,
38, 39, 51, 53, 82, 84, 126). The steep non-linear dose-response curve for nasal
tumours – indicating a disproportionate decrease in carcinoma incidence at low
concentrations – is most probably due to the fact that defence mechanisms of the
nose (mucociliary clearance, detoxification by dehydrogenase, DNA repair) are
very effective at low concentrations, but can be overwhelmed and inactivated at
high concentrations; consequently, cell and tissue damage and finally tumours
occur at high concentrations only. This also means that formaldehyde in
concentrations not leading to tissue damage most probably cannot act as a
complete carcinogen (causing initiation, promotion and progression), and as a
result is very unlikely to induce cancer by itself.
In several animal studies, inhalation of formaldehyde was not found to affect
reproduction.
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7. Existing guidelines, standards and evaluations
7.1 General population
The following recommendation was forwarded by IPCS/WHO (59): “The
formaldehyde air concentration allowed in living, sleeping and working rooms
should not be higher than 0.12 mg/m3 (0.1 ppm), in order to minimise the risk of
repeated or continuous low concentration exposure to formaldehyde”.
Using a linear-at-low-dose extrapolation, the United States Environmental
Protection Agency (EPA) developed an upper-limit unit-risk estimate of
1.6 x 10-2 /ppm continuous exposure to formaldehyde, in 1987 (32). This approach
was based solely on the dose-response for formaldehyde induced tumour
formation, assuming a five-stage model for carcinogenesis. The EPA subsequently
changed its risk estimate using a three-stage model, resulting in an upper-limit risk
of 6.1 x 10-3/ppm formaldehyde exposure. In 1991, the EPA further revised its risk
estimate using the levels of DNA-protein cross-links in the rat and monkey as an
indicator of delivered formaldehyde dose. The use of this information in a two-
stage model, based upon the goodness-of-fit of the data, yielded an upper-limit
unit risk estimate of 3.3 x 10-4/ppm. Thus, the use of mechanistic information
resulted in a 50-fold reduction in the estimation of carcinogenic risk to humans
from formaldehyde.
In 2002, the WHO/IPCS has published a review on formaldehyde (CICAD)
(119). They concluded that based on studies in both animals and humans,
formaldehyde is weakly genotoxic, with good evidence of an effect at site of
contact. Epidemiological studies taken as a whole do not provide strong evidence
for a causal association between formaldehyde and human cancer, although the
possibility of increased respiratory cancer cannot be excluded. Therefore, based
primarily upon data derived from laboratory studies, the inhalation of formal-
dehyde under conditions that induce cytotoxicity and sustained regenerative
proliferation is considered to present a carcinogenic hazard to humans.
7.2 Working population
Occupational exposure standards in various countries are shown in Table 6.
7.3 Evaluations of standards
7.3.1 The Netherlands
In 1981, DECOS concluded that formaldehyde is a proven genotoxic carcinogen
in experimental animals and that the induction of cancer in humans could not be
excluded (117). DECOS estimated that exposure to 0.1 mg/m3 or 0.5 mg/m3
formaldehyde, 8 hours/day, 5 days/week for 40 years with a life span of 75 years,
would result in maximal cancer risks of 1:40 000 and 1:10 000, respectively.
In 1987, however, DECOS updated the previous document and concluded that
an occupational exposure limit not exceeding 1.2 mg/m3 (1 ppm) formaldehyde,
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Table 6. Occupational exposure standards in various countries.
Country
-organisation
Occupational
exposure limit
Averaging
time
Notea Year of
adoptionb
Referencec
ppm mg/m3
The Netherlands 1 1.5 8 h 1986 (78)
2 3.0 15 min
Germany 0.30 0.37 8 h 4d
Sens
Unknown (35)
Great Britain 2 2.5 8 h Unknown (49)
2 2.5 15 min
Sweden 0.5 0.6 8 h Sens 1987 (106)
1.0 1.2 Ceiling Carc
Denmark 0.3 0.4 Ceiling Carc Unknown,
before 1994
(9)
Finland 0.3 0.37 8 h Unknown (101)
1 1.2 Ceiling
Norway 0.5 0.6 8 h Sens 1984 (36)
1.0 1.2 Ceiling Carc
Iceland 0.3 0.4 8 h Sens 1999 (114)
1.0 1.2 Ceiling
United States
–ACGIH 0.3 0.37 Ceiling Group A2d 1992 (2)
–OSHA 0.75 0.9 8 h Unknown (89)
–NIOSH 0.016 0.02 8 h Carc Unknown (85)
0.10 0.12 15 min
European Union Carc Unknown (86)
Cat 3
a. Sens, substance can cause sensitisation.
Carc, classification of carcinogenic properties.
b. Year that this limit was officially adopted.
c. Reference to the most recent official publication of occupational exposure limits.
d. Genotoxicity playing no or at most a minor part.
15 minutes TWA, virtually should not constitute an increased nasal cancer risk
(34). From studies in rats DECOS concluded that at subcytotoxic levels the risk of
induction of nasal cancer appears to be negligibly small.
7.3.2 United States
In 1989, the American Conference of Governmental Industrial Hygienists
(ACGIH) revised their assessment on formaldehyde. The proposed threshold limit
value (TLV) for formaldehyde was 0.37 mg/m3 (0.3 ppm) as a ceiling, with a
notation “suspected human carcinogen” (A2) (1). In the opinion of the ACGIH this
TLV as a ceiling should reduce the risk of sensory irritation for workers handling
formaldehyde or formaldehyde containing products. They also advised to reduce
formaldehyde workplace exposure to the lowest possible level in view of the
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reported dose-dependent carcinogenic effect in rats and mice, and the inadequate
epidemiological data on the cancer risk in man.
In 1992, OSHA responded to a remand by the Unites States Court of Appeals
for the DC Circuit (89). The final amendments lowered the permissible exposure
level for formaldehyde from 1 ppm as an 8-hour TWA to an 8-hour TWA of 0.75
ppm (0.9 mg/m3). It should be noted that the former standard had been challenged
in Unites States Court by both industry and labour. Four unions had challenged
the standard as being insufficiently protective. They contended that the former
permissible exposure limit was not low enough to eliminate all significant risk of
harm, from both cancer and from formaldehyde irritant effects.
The National Institute for Occupational Safety and Health (NIOSH) recommen-
ded an exposure limit of 0.02 mg/m3 (0.016 ppm) (8-hour TWA) and a 0.12
mg/m3 (0.1 ppm) 15 minutes limit (85).
7.3.3 Germany
In 2000, Deutsche Forschungsgemeinschaft set a “Maximale Arbeitsplatz-
konzentration” (MAK) value of 0.37 mg/m3 (0.3 ppm) for formaldehyde.
Formaldehyde is classified in category 4, which contains substances with
carcinogenic potential, for which genotoxicity plays no or at most a minor part.
No contribution to human cancer risk is expected at the MAK-value. The
classification is supported especially by evidence that increases in cellular
proliferation or changes in cellular differentiation are important in the mode of
action. To characterise the cancer risk, the manifold mechanism contributing to
carcinogenesis and their characteristic dose-time response relationships are taken
into consideration. Furthermore, formaldehyde is classified in germ cell
mutagenicity category 5. A risk of damage to developing embryos or foetuses is
not to be expected at concentrations below the MAK value. Therefore
formaldehyde is classified in group C for compounds which may influence
pregnancy.
7.3.4 Sweden
The most current consensus report for formaldehyde by the National Board of
Occupational Safety and Health was dated 25-8-1982. It was concluded that the
basis for occupational exposure standards should be the irritating effects of
formaldehyde on the respiratory organs and eyes. Formaldehyde has been shown
to be carcinogenic in animal studies. Epidemiological studies provide inadequate
evidence and cannot be used to assess carcinogenic effects on man.
7.3.5 IARC / WHO
The most recent evaluation by IARC on formaldehyde concluded that there was
limited evidence in humans for the carcinogenicity of formaldehyde (58). There is
sufficient evidence in experimental animals for the carcinogenicity of formalde-
hyde. The overall evaluation was that formaldehyde is probably carcinogenic to
humans (Group 2A).
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7.3.6 European Union
The European Union has classified the carcinogenic effects of formaldehyde in
category 3 (substances which cause concern for man owing to possible
carcinogenic effects but in respect of which the available information is not
adequate for making a satisfactory assessment) (Appendix 3).
8. Hazard assessment
8.1 Assessment of the health hazard
Formaldehyde occurs naturally in the environment and is produced physiologi-
cally by mammalian cells during metabolism. It has been used by man for over a
century in a variety of products and activities. The human cell can rapidly
detoxify lower levels of formaldehyde.
Airborne formaldehyde exposures can occur as vapour or as particles (solids or
mists) or as a combination of both. The relative intensities of vapour and particle
exposures vary with the industry and the job activities. The anatomic site of tissue
contact as well as the intensity of exposure depend on the physical form of the
compound. Inhaled formaldehyde vapour is usually efficiently removed by the
nose, mouth, and trachea, but in analogy with sulphur dioxide, some vapour
probably penetrates into the lower airways with mouth breathing during modera-
tely heavy or heavy work (55). Inhaled particles containing formaldehyde are
deposited in the respiratory system as a function of their aerodynamic character-
ristics and, given an appropriate aerodynamic diameter, may result in exposures
deep within the respiratory tract. The biological behaviour of formaldehyde
deposited in particulate form is unknown.
From the toxicological data base on formaldehyde it is evident that the critical
effects of formaldehyde are sensory irritation, and cytotoxicity induced regene-
rative hyperplasia (increased cell proliferation/increased cell turnover rates) and
metaplasia of the nasal respiratory epithelium accompanied by nasal carcinomas
in rats and possibly in mice after long-term exposure to high cytotoxic
concentrations.
Symptoms of formaldehyde exposure in humans start with sensory irritation
first experienced in the eyes, followed by perception of the odour, and then
irritation of the nose and throat, accompanied by discomfort, lachrymation,
sneezing, coughing, nausea and dyspnoea. A panel of independent experts
convened by the Industrial Health Foundation (IHF) studied all available data on
sensory irritation related to formaldehyde exposure (92). This IHF-panel
concluded that for most persons eye irritation does not occur until at least 1.2
mg/m3 (1.0 ppm) formaldehyde. This panel also observed that from controlled
studies in volunteers, it appears that moderate to severe eye, nose and throat
irritation does not occur for most individuals until exposure concentrations of
formaldehyde exceed 2.4-3.6 mg/m3 (2.0-3.0 ppm). The panel further concluded
that an occupational exposure limit of less than 0.6 mg/m3 (0.5 ppm) may be
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needed to prevent sensory irritation in a diverse working population, and therefore
recommended for formaldehyde an occupational exposure limit of 0.36 mg/m3
(0.3 ppm) as an 8-hour TWA with a ceiling value of 1.2 mg/m3 (1.0 ppm) (92).
However, according to the committees (DECOS and NEG) the database on
sensory irritation of formaldehyde reveals that at lower exposure levels sensory
irritation may still occur in substantial percentages of exposed individuals. For
instance, in a not well-documented study, more than 50% of occupationally
exposed workers complained of nasal discomfort after long-term exposure to an
average concentration of 0.26 mg/m3 (0.22 ppm; range 0.05-0.6 mg/m3 or 0.04-0.5
ppm) (120). Moreover, from a controlled study in volunteers it appeared that 19%
(n=3) of the exposed subjects (n=16) reported eye irritation at an exposure
concentration of 0.29 mg/m3 (0.24 ppm) (4). However, according to the IHF-panel
such a response is often considered of doubtful toxicological significance because
irritation responses of 15-20% may be obtained in unexposed volunteers as well
(92).
In experimental animals, irritation of eyes, nose, throat, and lungs were
observed at exposure concentrations higher than 2.4 mg/m3 (2.0 ppm). Kane and
Alarie determined in mice a 10-minutes RD50 for formaldehyde of 3.6±0.43
mg/m3 (3.0±0.28 ppm) (61). Compared to humans, experimental animals seem to
be less sensitive to stimulation of the trigeminal nerve by formaldehyde. More-
over, in view of the wealth of reliable data on sensory irritation in humans, the
irritation data on formaldehyde in experimental animals are considered of
secondary importance in terms of both hazard identification and risk assessment.
Overall, weighing the total body of data on sensory irritation, the committees
estimate that 0.3 mg/m3 (0.25 ppm) formaldehyde is the lowest exposure
concentration at which sensory irritation may occur in low but significant
percentages of exposed workers
Nasal carcinomas in rats have only been found at high, cytotoxic exposure
concentrations causing rhinitis, necrosis and regenerative hyperplasia and
squamous metaplasia of the nasal respiratory epithelium (60, 62, 81, 99). The
crucial role of tissue damage followed by hyperplasia and metaplasia of the nasal
respiratory epithelium in formaldehyde carcinogenesis has been demonstrated in a
convincing way (38, 39, 126) and has meanwhile been widely recognised (92,
118) and should therefore be included in human cancer risk assessment (29).
Despite differences in anatomy and physiology of the nose between rats and
humans, the upper respiratory tract defence systems are similar in both species
(82). It is, therefore, reasonable to conclude that the response of the respiratory
tract to formaldehyde will be qualitatively similar in rats and humans. If in
humans exposure of formaldehyde were to be accompanied by recurrent tissue
damage at the site of contact, formaldehyde may be assumed to have carcinogenic
potential in man. Correspondingly, if the respiratory tract tissue is not recurrently
injured, exposure of humans to relatively low non-cytotoxic levels of
formaldehyde can be assumed to be associated with a negligible cancer risk.
The committees observe that the majority of short- and long-term inhalation
toxicity studies with formaldehyde in experimental animals reveal a NOAEL of
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1.2 or 2.4 mg/m3 (1 or 2 ppm). However, in one 24-month inhalation study in rats,
2.4 mg/m3 (2 ppm) formaldehyde (lowest level tested) induced mild squamous
metaplasia of the epithelium lining the nasal turbinates (62). Moreover, a 13-week
inhalation toxicity study with formaldehyde, 1.2 mg/m3 (1 ppm), in rats was
inconclusive with respect to its effects on the nasal respiratory epithelium (125).
Furthermore, in two short-term inhalation studies in rats, slightly (and only
transiently) increased cell proliferation of the respiratory epithelium was seen in a
specific area of the nasal mucosa at formaldehyde exposure concentrations of 0.6
or 1.2 mg/m3 (0.5 or 1 ppm) (107, 108, 129). Finally, in one recently published
long-term inhalation toxicity/carcinogenicity study on formaldehyde in rats (60), a
low incidence of hyperplasia with or without squamous metaplasia of the nasal
respiratory epithelium was found at 0.36 mg/m3 (0.3 ppm). This low incidence
(4/32) was not statistically significantly different from that in controls (0/32), but
was nevertheless considered toxicologically relevant (i.e. formaldehyde induced)
because there was a clear dose-response relationship with the increased incidences
at the higher exposure levels being statistically significantly different from that in
controls.
The data in humans are less clear. Three meta-analyses of epidemiological
studies have shown inconsistent results. In two of them a significant relation
between exposure to formaldehyde and nasopharyngeal cancer risk was observed.
The association between formaldehyde exposure and nasal cancer was ambiguous
(15, 90). However, according to the committees in these meta-analyses the authors
did not correct for the unreported studies in which no cases of nasal cancers were
found. This most likely led to an overestimation of the overall relative risk of
nasopharyngeal cancer. In the third, more recent, published meta-analysis, relative
risks of 1.0 and 1.3 were found for nasal cancer in cohort and case-control studies,
respectively (31). In this meta-analysis a correction was made for underreporting.
Moreover, the authors evaluated the exposure potential for jobs included in the
general population case-control studies. The authors concluded that there was no
support for a causal relation between formaldehyde exposure and nasopharyngeal
cancer. The committees (both DECOS and NEG) endorse this conclusion and
further conclude that the currently available epidemiological database does not
provide support for a nasal cancer risk at the exposure levels lower than 0.3
mg/m3. Also from the epidemiological database it seems unlikely that exposure to
formaldehyde affects lung cancer risk (5, 6, 15, 18, 41, 46, 90). Overall, both
committees conclude that the currently available epidemiological database on
formaldehyde does not provide evidence for a respiratory tract cancer risk at the
experienced exposure levels. In correspondence to the previous evaluation of
formaldehyde by DECOS in 1987 (34), the committees endorse the conclusion
from 1987 that with prevention of cytotoxicity, carcinogenic effects will not
occur.
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8.2 Groups at extra risk
Allergic dermal sensitisation to formaldehyde in man occurs in 3 to 6% of the
general population. It is not possible to identify individuals with elevated risk for
allergic sensitisation a priori with a simple screening test. Skin sensitisation
constitutes a health risk in workers occupationally exposed to formaldehyde.
8.3 Scientific basis for an occupational exposure limit
The critical effect of formaldehyde is sensory irritation (LOAEL 0.25 ppm).
Another concern is cytotoxicity induced regenerative hyperplasia and metaplasia
of the nasal respiratory epithelium accompanied by nasal carcinomas in rats and
possibly in mice after long-term exposure to high cytotoxic concentrations.
High, cytotoxic formaldehyde vapour concentrations (≥10 ppm) can induce
nasal cancer in rats. A large body of data suggests an association between the
cytotoxic, genotoxic and carcinogenic effects of formaldehyde. Tissue damage
followed by hyperplasia and metaplasia of the nasal respiratory epithelium has a
crucial role in formaldehyde carcinogenesis. Thus, formaldehyde in non-cytotxic
concentrations not leading to tissue damage most probably cannot act as a
complete carcinogen. However, if human exposure of formaldehyde is accompa-
nied by recurrent tissue damage at the site of contact, formaldehyde may be
assumed to have a carcinogenic potential in man.
Formaldehyde is a skin sensitiser.
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9. Summary
Wibowo, Anton. The Nordic Expert Group for Criteria Documentation of Health
Risks from Chemicals and the Dutch Expert Committee on Occupational
Standards. 132. Formaldehyde. Arbete och Hälsa 2003;11:1-76.
Formaldehyde is a colourless, flammable, reactive gas, which readily polymerises,
and forms explosive mixtures with air and oxygen. It is used as a raw material in
chemical reactions, and as an intermediate in the manufacture of numerous
products. It has also a medical application as a disinfectant or preservative.
Inhaled formaldehyde is almost completely absorbed in the upper respiratory
tract in rodents. Formaldehyde is a normal metabolite in mammalians and is
rapidly metabolised to formate, which may be further oxidised to carbon dioxide.
Final elimination occurs via exhalation and via the kidneys.
The target organs of formaldehyde vapour are the eyes, nose, and throat. The
effects of concern are sensory irritation and cytotoxicity-induced regenerative
hyperplasia and metaplasia of the nasal respiratory epithelium accompanied by
nasal carcinomas in rats. Weighting the total body of data 0.25 ppm formaldehyde
is the LOAEL at which sensory irritation may occur in a low but significant
percentage of exposed workers. The majority of short- and long-term inhalation
animal studies reveal a NOAEL of 1-2 ppm. However, in a few studies slight
histopathological changes of the nasal respiratory epithelium were observed at
0.3-2 ppm.
Formaldehyde is genotoxic in a variety of experimental systems, including
rodents in vivo. There is overwhelming evidence that high, cytotoxic formal-
dehyde vapour concentrations (≥10 ppm) can induce nasal cancer in rats. A large
body of data suggests an association between the cytotoxic, genotoxic, and
carcinogenic effects of formaldehyde. The crucial role of tissue damage followed
by hyperplasia and metaplasia of the nasal respiratory epithelium in formaldehyde
carcinogenesis has been demonstrated in a convincing way. Thus, formaldehyde
in non-cytotxic concentrations most probably cannot act as a complete carcinogen.
However, if human exposure to formaldehyde is accompanied by recurrent tissue
damage at the site of contact, formaldehyde may be assumed to have carcinogenic
potential in man.
Formaldehyde-induced allergic contact dermatitis has been estimated to occur
in 3-6% of the population, and skin sensitisation by direct skin contact has been
induced with formaldehyde solutions. There is no consistent evidence of
formaldehyde being a respiratory sensisitiser.
Key words: allergy, cancer, contact dermatitis, cytotoxicity, formaldehyde, geno-
toxicity, irritation, nasal, occupational exposure limit, review, risk assessment
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10. Summary in Swedish
Wibowo, Anton. The Nordic Expert Group for Criteria Documentation of Health
Risks from Chemicals and the Dutch Expert Committee on Occupational
Standards. 132. Formaldehyde. Arbete och Hälsa 2003;11:1-76.
Formaldehyd är en färglös, lättantändlig, reaktiv gas som lätt polymeriserar och
bildar explosiva blandningar med luft och syre. Ämnet används som råmaterial i
kemiska reaktioner och som intermediär vid tillverkning av ett stort antal
produkter. Det har även medicinsk användning som desinfektionsmedel och
konserveringsmedel.
Inandad formaldehyd absorberas nästan fullständigt i de övre luftvägarna.
Formaldehyd är en normal ämnesomsättningsprodukt hos däggdjur och omvand-
las snabbt till format (myrsyra) som kan oxideras vidare till koldioxid. Slutlig
eliminering sker via utandning och via njurarna.
Målorgan för formaldehydånga är ögon, näsa och hals. Effekter av betydelse
är sensorisk irritation samt cytotoxiskt inducerad regenerativ hyperplasi och
metaplasi i nässlemhinnan, följt av näscancer hos råtta. Sammantaget bedöms
0,25 ppm vara den lägsta nivå (LOAEL) vid vilken sensorisk irritation uppträder
hos en liten men signifikant andel av exponerade arbetare. Merparten inhalations-
studier, såväl kort- som långtidsstudier, rapporterar en icke-effektnivå (NOAEL)
på 1-2 ppm. I några studier har man dock observererat små histopatologiska
förändringar av nässlemhinnan vid 0,3-2 ppm.
Formaldehyd är genotoxiskt i en rad experimentella system inklusive gnagare in
vivo. Det finns överväldigande bevis för att höga, cytotoxiska formaldehyd-
koncentrationer (≥10 ppm) kan inducera näscancer hos råtta. En mängd data pekar
på ett samband mellan de celltoxiska, genotoxiska och carcinogena effekterna av
formaldehyd. Vävnadsskada följt av hyperplasi och metaplasi i näsans respirato-
riska epitel spelar en avgörande roll i carcinogenesen vid formaldehydexponering,
vilket har visats på ett övertygande sätt. Formaldehyd i icke-cytotoxiska
concentrationer är därför troligen inte en komplett carcinogen. Om människor
exponeras för formaldehyd med upprepad vävnadsskada vid kontaktstället som
följd kan formaldehyd emellertid antas ha carcinogen potential.
Formaldehyd-inducerat allergiskt kontakteksem beräknas upträda hos 3-6% av
befolkningen och hudsensibilisering har inducerats via direkt hudkontakt med
formaldehydlösningar. Det finns inga entydiga bevis för att formaldehyd kan ge
sensibilisering via inandning.
Nyckelord: allergi, cancer, kontakteksem, cytotoxicitet, formaldehyd, geno-
toxicitet, gränsvärden, irritation, näs-, riskbedömning, översikt
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Formaldehyde monitoring data in occupational settings (59).
Appendix 2
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Appendix 3
Classification of substances with respect to carcinogenicity
Guideline 93/21/EEG of the European Community
4.2 Criteria for classification, indication of danger, choice of risk phrases
4.2.1 Carcinogenic substances
For the purpose of classification and labelling, and having regard to the current state
of knowledge, such substances are divided into three categories:
Category 1:
Substances known to be carcinogenic to man.
There is sufficient evidence to establish a causal association between human exposure
to a substance and the development of cancer.
Category 2:
Substances which should be regarded as if they are carcinogenic to man.
There is sufficient evidence to provide a strong presumption that human exposure to a
substance may result in the development of cancer, generally on the basis of:
• appropriate long-term animal studies
• other relevant information.
Category 3:
Substances which cause concern for man owing to possible carcinogenic effects but in
respect of which the available information is not adequate for making a satisfactory
assessment.
There is some evidence from appropriate animal studies, but this is insufficient to
place the substance in Category 2.
4.2.1.1 The following symbols and specific risk phrases apply:
Category 1 and 2:
T; R45 May cause cancer
However for substances and preparations which present a carcinogenic risk only when
inhaled, for example, as dust, vapour or fumes, (other routes of exposure e.g. by
swallowing or in contact with skin do not present any carcinogenic risk), the
following symbol and specific risk phrase should be used:
T; R49 May cause cancer by inhalation
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Category 3:
Xn; R40 Possible risk of irreversible effects
4.2.1.2 Comments regarding the categorisation of carcinogenic substances
The placing of a substance into Category 1 is done on the basis of epidemiological
data; placing into Categories 2 and 3 is based primarily on animal experiments.
For classification as a Category 2 carcinogen either positive results in two animal
species should be available or clear positive evidence in one species; together with
supporting evidence such as genotoxicity data, metabolic or biochemical studies,
induction of benign tumours, structural relationship with other known carcinogens, or
data from epidemiological studies suggesting an association.
Category 3 actually comprises 2 sub-categories:
a) substances which are well investigated but for which the evidence of a tumour-
inducing effect is insufficient for classification in Category 2. Additional
experiments would not be expected to yield further relevant information with
respect to classification.
b) substances which are insufficiently investigated. The available data are
inadequate, but they raise concern for man. This classification is provisional;
further experiments are necessary before a final decision can be made.
For a distinction between Categories 2 and 3 the arguments listed below are relevant
which reduce the significance of experimental tumour induction in view of possible
human exposure. These arguments, especially in combination, would lead in most
cases to classification in Category 3, even though tumours have been induced in
animals:
• carcinogenic effects only at very high levels exceeding the “maximal tolerated
dose”. The maximal tolerated dose is characterised by toxic effects which,
although not yet reducing life span, go along with physical changes such as about
10% retardation in weight gain;
• appearance of tumours, especially at high dose levels, only in particular organs of
certain species is known to be susceptible to a high spontaneous tumour
formation;
• appearance of tumours, only at the site of application, in very sensitive test
systems (e.g. intraperitoneal or subcutaneous application of certain locally active
compounds); if the particular target is not relevant to man;
• lack of genotoxicity in short-term tests in vivo and in vitro;
• existence of a secondary mechanism of action with the implication of a practical
threshold above a certain dose level (e.g. hormonal effects on target organs or on
mechanisms of physiological regulation, chronic stimulation of cell proliferation;
• existence of a species - specific mechanism of tumour formation (e.g. by specific
metabolic pathways) irrelevant for man.
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For a distinction between Category 3 and no classification arguments are relevant
which exclude a concern for man:
• a substance should not be classified in any of the categories if the mechanism of
experimental tumour formation is clearly identified, with good evidence that this
process cannot be extrapolated to man;
• if the only available tumour data are liver tumours in certain sensitive strains of
mice, without any other supplementary evidence, the substance may not be
classified in any of the categories;
• particular attention should be paid to cases where the only available tumour data
are the occurrence of neoplasms at sites and in strains where they are well known
to occur spontaneously with a high incidence.
